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ABSTRACT 
Cholesterol Lowering Effects of Bovine Serum Immunoglobulin in Human Participants 
with Mild Hypercholesterolemia. (August 2005) 
Melinda Lori Black, B.S., Texas Woman’s University 
Chair of Advisory Committee:  Dr. William McIntosh 
 
 
Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD).  
Interestingly, the consumption of dairy products, namely milk, has been shown to lower 
cholesterol.  The mechanism of action surrounding this observation has been attributed 
to the protein fraction of milk.  While there have been many studies evaluating the 
effects of dietary protein sources on cholesterol concentrations, few studies have 
evaluated specific animal protein components and no human clinical studies regarding 
the effects of animal plasma protein fractions on cholesterol metabolism have been 
conducted.  This study examined the effect of an oral serum bovine immunoglobulin 
protein fraction (bIg) derived from US Department of Agriculture approved beef (aged < 
30 months) on lipid indices in hypercholesterolemic humans.   
Participants included men and women (aged 25 – 70 years) with mild  
hypercholesterolemia (5.44-6.99 mmol/L) who were not receiving cholesterol-lowering 
medication.  Treatment consisted of the randomized, double blind, parallel group, 
placebo-controlled administration of 5 grams (g) bIg daily for 6 weeks (W) in 52 
participants (n = 26 each in treatment and control groups).  Mean (± SD) baseline 
treatment and placebo total cholesterol (TC) was 6.33 ± 0.1 mmol/L and 6.16 ± 0.1 
mmol/L respectively.  A repeated-measures multivariate analysis of covariance 
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(MANCOVA) covaried for change in total energy and alcohol intake, and a Tukey post-
hoc examination of the data showed that the bIg-treated group demonstrated a 
significant reduction in TC at 3-week (W) (5.98 ± 0.5 mmol/L; P < 0.05) and 6-week (W) 
(5.97 ± 0.7 mmol/L; P > 0.05) intervals compared to baseline.  The 6W concentration 
was significantly lower than the placebo group (P < 0.05).  Additionally, study findings 
displayed no significant changes in the placebo group or in any other lipid indexes or 
markers associated with hepatorenal or cardiovascular health.  Consumption of bIg 
appears to lower major lipid indexes associated with CVD. 
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CHAPTER I 
INTRODUCTION∗ 
Introduction 
Heart disease, one of the principal components of cardiovascular disease 
(CVD), is the leading cause of death in the United States (1).  The most common form 
of heart disease is coronary artery disease (CAD), the number one greatest killer of 
both men and women in the United States today (2).  Hypercholesterolemia, elevated 
blood cholesterol, is one of the major risk factors for CVD and for the development of 
coronary atherosclerosis, which is responsible for nearly three-fourths of all deaths from 
CVD (2,3).  In 2000, the growing numbers of individuals with elevated blood cholesterol 
levels prompted the National Committee for Quality Assurance, an independent, non-
profit organization sponsored by the American Heart Association and American Stroke 
Association, to choose five quality-of-care performance measures relating to preventing 
and treating CVD (4).  Included in these measures was total cholesterol (TC) screening 
and control in patients with CAD. 
Cholesterol is a “vital sign” for measuring an individual’s heart health due to its 
potential deleterious effects on the inner walls of the arteries that supply blood to the 
heart (5).  An estimated 105 million American adults, (49 million men and 56 million 
women), ages 20 and older, have borderline high or higher TC levels; a 37.7 million of  
 
This thesis follows the style and format of the American Journal of Clinical Nutrition. 
 
∗Part of the data reported in this chapter is reproduced with permission by the American Journal 
 of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition from “Cholesterol-
 lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia” 
 by Earnest CP, Jordan AN, Safir M, Weaver E, Church TS. Am J Clin Nutr 2005;81:792-8. 
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these individuals (16.9 million men and 21.8 million women) have TC levels reaching 
6.22 mmol/L (240 mg/dL) or higher (2).  As TC levels exceed 4.66 mmol/L (180 mg/dL),  
the risk for developing coronary heart disease (CHD) increases (2).  Current data  
 
indicates that during middle age, a 1% increase in TC can increase risk for CHD by  
3% (6).  Additionally, for individuals diagnosed with high cholesterol, a reduction of TC 
values by a mere 10 to 15% can roughly drop their incidence risk of CHD by 20 to 30% 
(7,8).    
Considerable evidence has demonstrated that TC reduction can halt or 
potentially reverse atherosclerosis along with minimizing the threat of myocardial 
infarction and CHD mortality (9,10).  Studies in adults with elevated blood cholesterol 
have shown that for every 1% reduction in TC levels, an individual can reduce their 
number of heart attacks by 2%, which equates to cutting the risk of heart attack in half 
by simply reducing TC by 25% (9).  An individual’s heart attack risk nearly doubles with 
a TC that reaches or is greater than 6.22 mmol/L (240 mg/dL) compared to a TC of 5.18 
mmol/L (200 mg/dL) (2).  Furthermore, a TC value of 5.70 mmol/L (220 mg/dL) 
correlates to nearly a two-fold elevation in incidence of CHD as compared to a TC of 
4.66 mmol/L (180 mg/dL) (2).  According to the American Heart Association (AHA), a 
decrease in an individuals total mortality risk may be achieved by lowering elevated TC 
levels to a range of 4.15 mmol/L (160 mg/dL) to 5.15 mmol/L (199 mg/dL) for primary 
heart disease prevention, meaning prior to a cardiac event (11).  As noted, modest 
reductions in TC can significantly influence an individual’s CHD risk profile.  The latest 
National Cholesterol Education Program Guidelines for Detection, Evaluation and 
Treatment of High Blood Cholesterol in Adults (NCEP) recommends that all adults older 
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than 20 years (y) of age know their cholesterol levels and, in accordance with the AHA 
guidelines, recommends cholesterol testing at least once every five years for all healthy 
adults (12,13,14).   Elevated serum TC is clearly associated with a high risk of CHD as 
confirmed by the Lipid Research Clinics-Coronary Primary Prevention Trial (15).  
However, the prediction of risk for CHD greatly improves when low density lipoprotein 
cholesterol (LDL-C) levels are measured (16).  In order to specifically zero in on heart 
disease risk, the NCEP guidelines recommend lipid panel testing or a lipoprotein profile, 
a test that defines all the blood components of TC, as the preferred initial screening 
protocol for detecting CHD (12).   
Elevated TC and LDL-C are significant risk factors in the development of heart 
or cardiovascular disease (CVD) with elevated blood cholesterol being one of the most 
modifiable risk factors for CHD.  Even mild degrees of hypercholesterolemia, when due 
to increased levels of LDL-C, are associated with dramatic increases in heart disease, 
and indirectly, stroke risk (2,12).  The lowering of plasma LDL-C has clearly shown a 
reduction in coronary risk (12,17).  Every 1 mg/dL (0.026 mmol/L) reduction in LDL-C 
can be associated with an approximate 1 to 2% reduction in relative risk of CHD 
(15,18).  
 Modifiable dietary risk factors in cholesterol reduction.  Controlling the 
modifiable risk factors most strongly associated with the development of CHD including, 
but not limited to, TC and LDL-C rely strongly on Therapeutic Lifestyle Change (TLC) 
recommendations of the Adult Treatment Panel III (ATP III) of the NCEP (3).   The 
NCEP puts strong emphasis on the use of TLC as the first line of intervention in 
managing CHD risk (3).  TLC recommendations are characterized by four lifestyle 
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change components including, but not limited to, decreased dietary intake of saturated 
fats (less than 7% of total calories) and cholesterol (less than 200 mg daily), increased 
intake of viscous fiber (10-25 gm of daily soluble fiber), and the addition of either plant 
stanols or sterols (2 gm daily) (12).  In combination, TLC components can lower LDL 
cholesterol by ≥ 20% (3).  With NCEP’s strong emphasis on modifiable risk factors, 
dietary management and weight reduction, for lowering TC and heart disease risk, 
studies show the TC lowering effect of the NCEP Step I diet ranging from + 5% to – 
40% with an overall average decrease in TC of 20% (12). The NCEP Step I diet, which 
was intended as the dietary starting point for individuals with high cholesterol, limited 
total fat and saturated fat to ≤ 30% and 10%, respectively, of total caloric intake and 
restricted dietary cholesterol intake to < 300 mg/day (d).  Average reductions in LDL-C 
with the NCEP Step I and Step II diet were 12% and 16%, respectively (19).  The NCEP 
Step II diet goals were designed for individual’s with TC levels > 240 mg/dL and already 
following the Step I diet. NCEP’s Step II diet goals were lower for saturated fat (< 7 %) 
and dietary cholesterol (< 200 mg/d) intake.  The TLC diet, detailed in Table 1 (20), is 
known as the “next generation” of NCEP’s Step diets (20).   
To enhance the effectiveness of TLC components, the AHA highlights the 
potential cholesterol-lowering benefits of a daily diet that includes vegetable soy protein 
and nuts (21).  Study observations involving intensive dietary intervention that combine 
modified NCEP and AHA dietary recommendations into a plant-based meal plan, the 
Portfolio diet, consisting of soy protein (~ 50 gm/d) replacing dairy protein with the 
addition of soluble fiber (oats, barley and psyllium), almonds (around 35 gm/d) and plant 
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sterols have proven to lower LDL-C concentrations by an estimated 30%, which would 
equate to an average 13-20% reduction in the general population (3,22,23,24).   
 
 
 
 Nutrients   Percent of Total Calories 
Carbohydrate 
 
Protein  
Total Fat 
50–60%, mainly foods rich in complex 
carbohydrates 
~ 15%, some animal protein may be 
replaced with soy protein 
25-35% 
    Saturated Fat < 7% 
    Polyunsaturated Fat ≤ 10% 
    Monounsaturated Fat ≤ 20% 
 Recommended Intake Amounts 
   Fiber ** 10-25 gm of viscous (soluble) fiber  
   Cholesterol < 200 mg/d 
 
   Plant-derived Sterols 
   or Stanols **  
 
2 gm/d 
 
  
     Total Calories 
Balance energy intake with moderate 
physical activity expenditure (contributing   
~ 200 calories/day to maintain desirable 
body weight and prevent weight gain 
 * American Heart Association 2001. Step I, Step II and TLC Diets. 
 Internet: http://www.americanheart.org/presenter.jhtml?identifier=4764 
 ** Therapeutic options for lowering LDL-C. 
 
Table 1 
Therapeutic lifestyle change diet in ATP III* 
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The average cholesterol reduction that can be obtained from a combination of 
dietary change, weight reduction and regular exercise can vary widely between 
individuals due to a broad number of parameters, including baseline lipoprotein levels, 
weight change amounts, genetic factors, exercise consistency and degree of adherence 
to a modified diet (12,25).  Additionally, for many individuals, monumental challenges 
exist in implementing these changes.  Although dietary counseling and modification 
remain the cornerstones of therapy for virtually all lipid modification trials, an alternative 
to lowering cholesterol is the use of cholesterol-lowering medications.     
Medication management of hypercholesterolemia.  Medication management 
of elevated cholesterol has been shown to be extremely effective in lowering TC and 
LDL-C values (26,27).  When optimal control of LDL-C is unobtainable with nutritional 
screening and dietary intervention strategies, one or more antilipemic drugs, such as 
statins, are often prescribed to aid in reducing CHD risk (27).  Unfortunately, although 
study evidence has demonstrated that these medications are effective in reducing 
cholesterol values and mortality risk, some individuals may experience negative 
sequealea, primarily musculoskeletal side effects, contraindicating their use (28-33).  
Franc, et al. concluded that the incidence of adverse muscle-related side effects, 
including, but not limited to muscle pain, cramps, weakness and tendonitis associated 
with pain, is likely underreported by published research trials (33).  In this study, 815 
adult hyperlipidemic individuals taking statins and complaining of muscle-related side 
effects (noted above) were interviewed about their symptoms and asked to complete a 
self-administered questionnaire detailing their complaints.  Out of the 815 individuals 
interviewed, 165 reported negative muscle side effects that they attributed to lipid 
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lowering drug treatment (LLT).  The questionnaires completed by 133 of these 
individuals showed 39% having to resort to analgesics at least once for muscle pain 
relief.  The most frequent symptom reported was muscle cramps, however 40% of the 
patients in this study also reported associated tendonopathies.  Keeping in mind that 
potential problems can occur with medication management of cholesterol-reduction, the 
continued investigation of alternative cholesterol-lowering options is warranted.  
Bovine immunoglobulin (bIg) supplements may be viewed as one the newest 
experimental cholesterol-lowering alternatives (34,35).  In the event that bIg 
supplements are found safe and effective in reducing cholesterol, they could become 
viable weapons in the prevention and treatment of cardiovascular disease.  
 
Objectives of This Research 
No known published human studies existed that demonstrated the effect of a 
bovine serum-derived, highly concentrated, immunoglobulin protein supplement on lipid 
reduction, specifically TC and LDL-C.  The primary objective of this current trial was to 
assess the cholesterol-lowering effects of a bovine immunoglobulin-rich supplement, 
Proliant’s ImmunoLin™, on blood lipid indices, mainly TC and LDL-C, in hyperchol- 
esterolemic human subjects.  The specific aims of this investigation were: 
1. To determine whether Proliant’s ImmunoLin™ supplement would result in a 
statistically significant reduction in TC and LDL-C in the ImmunoLin™ treatment group; 
2. To determine if a six-week ingestion of 5g daily of Proliant’s ImmunoLin™ 
supplement would reduce TC and LDL-C concentrations by at least 8 to 10% in the 
hypercholesterolemic human study participants.  
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Definitions 
The following are operation definitions of key terms in this study:  
1. Atherogenic Index (AI):  a formula used to compare the atherogenic potential 
of dietary fats defined as the ratio of non-HDL-C to HDL-C or [(TC – HDL-C) / HDL-C] 
(36,37).  The AI should be as low as possible, below 4.0 for men and 3.5 for woman 
(37). 
2. Atherosclerosis (coronary artery disease):  a slow, progressive disease 
process that involves a hardening of the arteries, or plaque formation, resulting from 
excess accumulation and deposition of fatty substances, cholesterol, cellular waste 
products, calcium and fibrin within the inner lining of the artery.  A partial or total block 
of arterial blood flow can result in hemorrhage into the plaque or formation of a 
thrombus on the plaque’s surface followed by a heart attack or stroke (block of the 
entire artery).  The disease often begins during childhood and progresses with age (38).   
3. Body Mass Index (BMI):  a measurement, despite the inability to distinguish 
between excess fat and muscle mass, where weight in kilograms is divided by height in 
meters squared (kg/m2) and is strongly correlated with body fat content, disease 
morbidity and mortality risk in all population groups (Table 2) (39).  BMI measurements 
are closely associated with measures of body fat (39).  Relative CVD risk factors and 
incidence rates, average blood pressure (BP), and TC concentrations increase in a 
graded fashion with rise in BMI accompanied by a decline in average HDL-C (40).  
Because BMI charts (Table 3) (39) can be easily and effectively utilized in predicting the 
development of health problems related to excess weight, they have recently become 
the medical standards used to measure overweight and obesity (41).  
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4. Casein:  a primary milk protein comprising 75 - 80% of total milk protein (42). 
5. Chem-16:  a blood chemistry profile measuring the following blood indexes: 
C-reactive Protein (CRP), total cholesterol (TC), triglycerides (TG), HDL count (HDL-C), 
LDL count (LDL-C), cholesterol ratios (TC/HDL, LDL/HDL), blood glucose (BG), uric acid 
(UA), blood urea nitrogen (BUN), creatinine (Cr), BUN/creatinine ratio, sodium (Na), 
potassium (K), chloride (CL), calcium (Ca), phosphorus (Ph), protein (Pro), albumin (A), 
globulin (G), A/G ratio, bilirubin (bili), alkaline phosphatase (ALK), lactate 
dehydrogenase (LDH), liver enzymes (AST/SGOT, ALT/SGPT, GGT), and iron (Fe). 
  
 
  
* Weight-control Information Network (WIN): An information service of the National Institute of 
   Diabetes & Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH). 
   Do You Know the Health Risks of Being Overweight? Heart Disease and Stroke.  
   Internet: http://www.niddk.nih.gov. 
Table 2 
Body Mass Index (BMI) chart* 
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6. Cholesterol:  a fat-like substance produced by the liver and transported 
through the body to perform normal body functions, such as production of bile and 
Vitamin D (43).  Cholesterol is found in the blood, every body cell, and in animal-based 
foods.  TC values can help determine relative risk for developing heart disease because 
excess blood cholesterol can have deleterious effects on the inner walls of the arteries 
that supply blood to the heart (atherosclerosis), possibly compromising heart function 
(12,44).  For general cholesterol levels considered acceptable for the average adult with 
no other know heart disease risk factors, see Table 4 (12).  
 
 
BMI 
 
Classification 
Waist less than or 
equal to 
40 in. (men) or 
35 in. (women) 
Waist greater than 
40 in. (men) or 
35 in. (women) 
18.5 or less Underweight -- N/A 
18.5 - 24.9 Normal -- N/A 
25.0 - 29.9 Overweight Increased High 
30.0 - 34.9 Obese High Very High 
35.0 - 39.9 Very Obese Very High Very High 
40 or greater Extremely Obese Extremely High Extremely High 
* Partnership for Healthy Weight Management: Body Mass Index and Waist Size.  
   Internet: www.consumer.gov/weightloss/bmi.htm 
Table 3 
Risk of associated CVD according to BMI and waist size* 
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7. C -Reactive Protein (CRP):  an acute phase plasma protein synthesized by 
liver parenchymal cells and released into the blood stream released into the 
bloodstream in response to various immune system stressors, such as infection, 
inflammation or trauma (45).  Additionally, CRP levels will rise due to heart attack, 
stroke or other cardiovascular events (46).  Elevated CRP levels may be associated 
with arterial inflammation and have been shown to predict cardiovascular events 
      CHOLESTEROL VALUES 
LDL CHOLESTEROL 
 Less than 100   Optimal Goal  
 100 to 129   Near/Above Optimal  
 130 to 159   Borderline High  
 160 to 189   High  
 190 or higher   Very high (definite risk)  
HDL CHOLESTEROL 
 Less than 40   Low (High Risk)  
 60 or higher   High (Optimal)  
TRIGLYCERIDES 
 Less than 150   Optimal Goal 
TOTAL CHOLESTEROL 
 Less than 200   Desirable Optimal Goal  
 200 to 239   Borderline High  
 240 or higher   High  
Table 4 
ATP III (NCEP) classification of LDL-C, TC and 
HDL-C (mg/dL)1
  1 Summary of the Third Report of the National Cholesterol Education 
 Program (NCEP) Expert Panel on Detection, Evaluation and Treatment 
of High Blood Cholesterol in Adults (Adult Treatment Panel III). May 
2001. Internet: http://www.nhlbi.nih.gov/guidelines/cholesterol. 
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(37,47).  According to the Physician’s Health Study, people with increased CRP levels 
are at risk for heart attack and stroke (48,49). 
8. Coronary artery disease (CAD):  disease of the coronary arteries resulting in 
impaired blood flow and supply to the heart muscle.  Commonly, the insufficient or 
obstructive blood flow can be attributed to atherosclerosis, which can cause a narrowing 
or blockage of the vessels due to the plaque (cholesterol) buildup in the artery walls 
(50).  Symptoms of CAD may include shortness of breath and/or angina (chest pain) 
followed by a potential myocardial infarction (heart attack) or disorder of heart rhythm 
(arrhythmia or dysrhythmia) that could result in sudden death (50). 
9. High Density Lipoprotein Cholesterol (HDL-C):  the "good" cholesterol that 
binds and transports cholesterol in the blood away from body cells and tissues and back 
to the liver for excretion from the body.  HDL-C helps keep LDL-C from building up in 
the walls of the arteries.  An inverse correlation exists between HDL-C levels and heart 
disease risk.  HDL-C values < 40 mg/dL result in a substantially higher risk for heart 
disease and heart attack (estimates are age adjusted) (2), while levels ≥ 60 mg/dL help 
protect against heart disease (12, 44).  The average HDL-C for men is approximately 45 
mg/dL and 55 mg/dL for women (12).  High levels of HDL-C are clinically more 
desirable. Table 4 details HDL-C level classifications.   
10. Hypercholesterolemia:   borderline to undesirable TC cholesterol levels. 
11. Immune milk:  bovine milk obtained from hyperimmunized cows containing  
varying amounts of immunoglobulin proteins due to bovine regional variations (51,52). 
12. Immunoglobulins (Ig):  specialized proteins produced by the body in 
response to challenge by a foreign molecule.  They are found mainly in serum, 
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colostrum, and milk, and serve to protect the body from microbial, viral, and fungal 
invasion (53).  Immunoglobulin comprises at least 25% of the protein content of serum. 
13. ImmunoLin™:  a natural, lactose-free, allergy-free, concentrated immuno- 
globulin protein isolate extracted from bovine serum produced by Proliant, Incorporated 
(54).  ImmunoLin™ (54) is derived from cattle specifically raised for food (54,55).  Table 
5 details the contents of the ImmunoLin™ supplement at the treatment dosage level 
(55). 
 
 
 Table 5 
 ImmunoLin™ supplemental study product with detailed   
  contents listing and percentage amounts1 
 
 
 
 
 
 
 
 
 
 
 
 
   
 1 Wilke Resources: ImmunoLin™ vs. Colostrum. Internet: www.wilkeinternational.  
   com/WILKEresources/ImmunolinColostrum.htm. 
2 GH – Growth Hormone; IGF – Insulin Growth Factor; TGF – Transforming Growth   
   Factor  
 
 
 
 
14. Low Density Lipoprotein Cholesterol (LDL-C):  the transporter for most of 
the cholesterol throughout the body and the primary target for cholesterol lowering 
Components ImmunoLin™ (10 capsules) 
 Calories  20 
 Protein  5 gm 
 Total Protein  88.6% (by weight) 
Immunoglobulin G (IgG)  46% - 53% (of total protein) 
  - Other Immunoglobulins (Ig)  IgM, IgE, IgD, IgA 
 (B-lactoglobulin)  0% 
 Proline-rich polypeptides  5% (of total amino acids) 
  - Growth factors present2  GH, IGF, TGF, etc. 
 Fat  0.2% 
 Lactose  0% 
 Ash  6.5% 
 Moisture  4% 
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therapy.  As the predominant atherogenic protein, excess blood levels of LDL-C, also 
known as the "bad" cholesterol, can result in cholesterol (plaques) build up on artery 
walls that can result in damaging accumulation and blockage.  Heart disease and stroke 
risk increases with rising LDL-C levels (12,5).  LDL-C levels < 100 mg/dL are desirable 
(Table 4) (12).   
15. Lipid panel (profile) test:  a blood test used to measure heart health status 
via assessment of TC, LDL-C, HDL-C, and triglycerides (TG) (12).  The latest National 
Cholesterol Education Program (NCEP) Guidelines for Detection, Evaluation and Treat- 
ment of High Blood Cholesterol in Adults lists lipid panel testing as the preferred initial 
test for detecting coronary heart disease, rather than just screening for TC and HDL-C 
alone (4,44).  Table 4 (12) displays NCEP guidelines for lipid panel measures (12). 
16. Trans fatty acid (TFA):  also known as trans fats, TFA are naturally 
occurring in some meat and dairy products.  However, they are also commercially 
produced during the partial hydrogenation process of vegetable oils, which converts oil 
into a more stable liquid or semi-solid form (56).  Trans fats are present in variable 
amounts in a wide range of commercially prepared foods containing partially hydrogen- 
ated vegetable oils.  The AHA reports that partially hydrogenated vegetable oils provide 
about three-fourths of U.S. dietary TFA intake, which is estimated to range from 2.6 
gm/d to 12.8 gm/d (57).  Studies suggest that trans fat intake raises LDL-C and lower 
HDL-C levels, thus, increasing the risk of coronary heart disease (57). 
17. Whey protein:  a milk protein that accounts for about 20% of the total  
protein found in milk (58).  The purest form of whey protein is whey protein isolate, 
which is 90% to 95% protein and is virtually fat and lactose free (58).  
 
           
 
15 
Assumptions of This Research 
The following assumptions may have affected the results of the study: 
1. All subjects will answer all questionnaires truthfully and reliably. 
2. All subjects will be compliant with required supplement regimen. 
3. All subjects will maintain current weight, exercise habits and dietary intake 
amounts while avoiding the initiation of new vitamin and/or mineral supplements and 
medications within 6W prior to the study. 
4. All subjects currently on standard medical therapy for disease-related 
conditions will continue current medical regimen during the study. 
5. The food frequency questionnaire is a valid and reliable food intake 
assessment tool. 
 
Limitations of This Research 
The following limitations may have confounded the study: 
1. Broad age range of subjects included. 
2. All subjects must be competent in reading and understanding the food 
frequency questionnaire. 
3. Patient compliance with supplement protocol. 
4. Limited sample size. 
5. Pill counting utilized to determine treatment compliance. 
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Significance of This Research 
This research is the first to measure the effects of an oral, highly concentrated 
source of bovine globulin protein on cholesterol indices in mildly hypercholesterolemic 
human subjects.  Overall, this research contribution will add valuable information to the 
limited research available on animal globulin proteins, immunoglubulins, and their 
impact on human blood lipids.  Furthermore, these results should warrant continued 
research surrounding medication alternatives and adjunct therapies for cholesterol 
reduction and management.  
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CHAPTER II∗ 
REVIEW OF THE LITERATURE 
The following chapter will discuss cholesterol in the body and the diet, the 
components of dairy products responsible for cholesterol reduction, dietary supplement 
management of elevated cholesterol and ImmunoLin™ product purity standards.     
 
Introduction 
High cholesterol levels are a significant contributor to heart disease (HD) and 
lowering elevated cholesterol levels has been scientifically proven to prevent HD and 
prolong life.  Cholesterol, a soft, waxy substance synthesized primarily endogenously 
via the liver and acquired exogenously via the diet, is transported throughout the 
plasma as phospholipid, triglyceride and lipoprotein complexes (59).  The body 
produces approximately 80% of its own cholesterol daily, between 800-1000 mg, while 
daily dietary sources contribute the remaining 20%, about 300 mg, to the total daily 
input of cholesterol in the body (60,61).  
 Blood cholesterol and lipid transport.  The liver is involved in orchestrating 
cholesterol balance across the entire body in that it is responsible for cholesterol 
uptake, breakdown and excretion.  The various synthesis and transport pathways of 
lipids throughout the body can be characterized as exogenous, endogenous or reverse 
cholesterol transport (62).  Focusing on the exogenous lipid pathway, following intake of  
 
∗Part of the data reported in this chapter is reproduced with permission by the American Journal 
 of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition from “Cholesterol-
 lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia” 
 by Earnest CP, Jordan AN, Safir M, Weaver E, Church TS. Am J Clin Nutr 2005;81:792-8. 
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a meal, the epithelial cells of the intestinal mucosa mobilize dietary fat, TG and 
cholesterol into blood circulation by packaging them inside chylomicrons, complex 
protein coats (62).  Circulating chylomicrons release TG’s to the muscle cells and 
adipose tissue and deliver remaining dietary cholesterol to the liver via chylomicron 
remnant receptors present on hepatocytes (59).  Between meals, the liver manufactures 
and secretes lipoproteins, TG and cholesterol esters back into plasma (endogenous 
lipid transport) to form very low density lipoproteins (VLDL), the precursors to LDL-C.  
Lipoprotein lipase (LPL) metabolizes VLDL cholesterol, releasing fatty acids into the 
muscle and adipose cells.  Remnant VLDL particles are absorbed by liver cell low 
density lipoprotein (LDL) surface receptors, the remaining LDL-C is cellularly 
scavenged, and free cholesterol is released into cells whereby excess accumulation 
can occur within the arteries (62).   
Removal of LDL-C is mediated through LDL liver cell surface receptors.  These 
LDL receptors function by binding cholesterol particles from the blood and transporting 
them into the cells.  The number of active LDL receptors on the surface of hepatocytes 
is directly correlated with the amount of LDL-C that is present in the bloodstream.  LDL-
C, the main carrier of circulating cholesterol in the body, is responsible for the 
deleterious formation of arterial plaque and atherosclerosis (62).   
The final cholesterol transport process, often referred to as reverse transport, 
involves the synthesis of HDL-C, a lipoprotein involved in the prevention of 
atherosclerosis via its participation in the extraction of free cholesterol particles from 
artery walls and disposal of them through the liver (62).  Elevated levels of LDL-C 
accompanied by depressed levels of HDL-C (high LDL/HDL ratios) are risk factors for 
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atherosclerosis, while low LDL-C levels accompanied by high HDL-C values (low LDL/ 
HDL ratios) are desirable.  
 
Exercise and Serum Cholesterol 
 Serum cholesterol is influenced by many risk factors.  Some are non-modifiable, 
such as heredity, gender, and age, as opposed to those that are more modifiable, such 
as exercise, diet and weight.  The National Cholesterol Education Program (NCEP) 
promotes exercise, dietary modification and resultant weight loss for the treatment of 
abnormal lipoprotein.  Inactivity is one of the four major risk factors for coronary artery 
disease (44).  Increases in physical activity can benefit the heart and circulation, 
including improve cholesterol and lipid levels, reduce arterial inflammation, assist in 
weight loss, and help to keep blood vessels elastic and open (44).  Dose response 
relationships between training volume (15 to 20 miles of brisk walking or jogging) and 
blood lipid changes exist whereby the amount of physical activity as it relates to large 
muscle mass usage and caloric expenditure have been deemed as the stimulus for 
altering blood lipids and lipoprotein levels (63).  Based on a cross-sectional analysis 
report of various exercise-induced lipoprotein change studies, the average individual 
participating in regular aerobic exercise, which was characterized as jogging and/or 
brisk walking to produce a weekly energy expenditure ≥ 1200 calories, may potentially 
achieve 2 to 8 mg/dL increases in HDL-C levels and decreases in TC and LDL-C 
averaging ~ 4 mg/dL (63).  Additionally, upon further review of the study literature, 
baseline study levels of TC and LDL-C along with variations in exercise intensity did not 
prove to be determinants for exercise-induced alterations in TC and LDL-C values.  
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However, in studies evaluating exercise-induced HDL-C increases, HDL-C baseline 
levels were shown to strongly positively correlate with increases in HDL-C levels 
following exercise, whereby individuals entering the study with normal or slightly 
elevated HDL-C values attained the greatest HDL-C increases upon trial conclusion 
(63).  Overall, for the majority of individuals, studies indicate that training volumes of 15 
to 20 miles of jogging or brisk walking expending between 1200 to 2200 calories per 
week will produce favorable lipoprotein effects (63).   
Body fatness and effects on cholesterol.  A second variable that can 
influence lipid levels dramatically is a loss in body weight, especially body fat loss.  
Total and LDL cholesterol values are traditionally improved with exercise, especially 
accompanied by weight-loss (64).  Weight loss or body fat loss actually reduces visceral 
adiposity and fat mass and improves insulin resistance which promotes an increase in 
circulating HDL-C levels, lowers TG (another risk factor for heart disease) and 
decreases LDL-C via lipoprotein lipase (64-67).  Weight loss accompanied by 
decreases in body fat can significantly reduce an individual’s heart disease risk factors 
by positively affecting lipid levels (12).  Reductions in body fat and weight, coupled by 
increases in lean body mass (LBM), can be accomplished through adhering to a routine 
exercise program and a modified caloric, low-fat eating plan.  Managing not only the 
amounts but also the types of foods eaten to control weight will help reduce an 
individual’s cholesterol and cardiac risk (12).  For every 10 pounds of weight loss, an 
individual can lower their TC by 5-8% (12).  Weight gain prevention should be 
emphasized for all individuals (12).  
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Dietary Cholesterol and Coronary Artery Disease Risk 
The body produces all of the cholesterol that it needs to maintain a constant 
level for the body.  However, blood cholesterol may be altered by elevated intake of 
dietary cholesterol and saturated fat, including foods such as meat, full fat dairy items, 
and baked goods.  The average American man consumes ~ 337 mg of dietary 
cholesterol daily and the average woman ingests ~ 217 mg/d. (21).  On the average, 
20% of total blood cholesterol comes from the diet (60).  Elevated dietary cholesterol 
intake can raise blood cholesterol values, which is associated with plaque build-up that 
can narrow or block blood vessels.  The dietary strategy to reduce the risk of CAD 
focuses primarily on reducing total fat (68,69), saturated fatty acids (68-70), and 
cholesterol intake (69-71).  Furthermore, elevated dietary saturated fat and cholesterol 
intake down-regulates LDL receptor-mediated clearance function via the liver, increases 
HMG-CoA reductase activity, and results in an increase in circulating cholesterol (72).  
Regulation of HMG-CoA reductase activity is the rate-limiting step in cholesterol 
biosynthesis (72).  Additionally, study results have demonstrated a significant positive 
correlation between plasma TC and LDL-C levels and the susceptibility of LDL to 
oxidation; consumption of low saturated fatty acid diets decreased both (73).  To lower 
LDL-C concentrations, LDL receptor function must be stimulated, and adhering to a diet 
that is low in saturated fat and cholesterol can accomplish this goal.   
Dietary modifications that may be beneficial for lowering cholesterol and 
managing weight include (12): replacing animal products containing high saturated fat 
content with lean meats and skim dairy products to help lower TC values by 8 - 10%, 
and in turn, reduce CHD risk; limiting total dietary cholesterol intake to < 200 mg daily to 
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help reduce TC by 5 - 8%; increasing daily soluble dietary fiber intake with the addition 
of oats and/or psyllium husk to help attain a 3 - 5% reduction in LDL-C; and reducing 
trans fatty acid intake daily.  Controlling the dietary blend of cholesterol lowering foods 
(noted above) can affect cholesterol reduction up to 20 to 30% (12). 
 
Dairy Products and Cholesterol Reducing Agents 
 As noted above, lowering cholesterol through dietary management is possible 
by maintaining an eating plan tailored to include specific cholesterol lowering foods daily 
(12,26).  Milk and dairy products, because of their high saturated fat and cholesterol 
levels, are often included among the forbidden foodstuffs for people with high serum 
cholesterol levels.  However, despite the fact that whole milk dairy products may 
negatively affect cholesterol levels, one human study conducted over five weeks 
compared the effects of daily dietary additions of 2 liters (L) skim milk, yogurt and full 
cream milk in teenage boys.  The results of this study showed no rise in TC 
concentrations in the full cream milk group.  Furthermore, this study also demonstrated 
that HDL-C and the percentage HDL/TC levels rose highest within the first week with 
full cream milk consumption (74).  A review panel concluded that whole milk may not 
affect blood lipids due to its fat content and fat composition as previously thought (75).  
Cholesterol-lowering effects of milk.  Interestingly, some cholesterol-lowering 
effects have been found to be directly associated with the consumption of whole and 
skimmed dairy products, namely milk and yogurt (76-80).  The potential mildly 
hypocholesterolemic effect of milk and fermented milk products were initially proposed 
based on a study conducted by Mann (81) involving the Masai people of Africa.  Despite 
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their low incidence of CVD, the Masai's dietary intake consists of large amounts of 
meat, milk and blood products, and a diet that could be described as atherogenic.  In 
this report, consumption up to 8.3 liters (L) of milk daily by Masai men aged 16–23 
years, resulted in lower TC, despite weight gain in the participants.  Of importance to 
note, this study was terminated after three weeks instead of at the four week study 
protocol due to the extreme rise in milk consumption from 3-5 L/day (d) before study 
initiation to 8.3 L/d by the fourth day of the study, lack of encouraged increases in 
physical activity and resultant weight gain.  The study concluded with a positive 
correlation between increases in milk consumption and cholesterol reduction, noting 
that the greater the milk intake, the greater the decrease in cholesterol concentration.  
No rationale was provided to explain the decline in cholesterol values despite subject 
weight gain, however studies have also focused on inter-individual differences in 
metabolic responses to dietary saturated fat and cholesterol, along with alternate 
explanations for low blood cholesterol in African herders, which has been attributed to 
physiological adaptations that reduce cholesterol synthesis (82,83).  Nevertheless, 
Mann concluded that a component in milk decreased cholesterol concentrations and 
that milk acts as an inhibitor of cholesterol synthesis.  These study findings are difficult 
to extrapolate to healthy Americans where epidemiological, clinical, and biochemical 
studies have shown that dietary saturated fat and cholesterol raise total plasma 
cholesterol and LDL-C levels and induce atherosclerosis (12).  Nevertheless, there is 
considerable evidence in humans that some individuals are more sensitive to a high fat, 
high cholesterol diet than others (84). Additionally, it is highly likely that there is a major 
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genetic component of dietary responsiveness, however, the genes involved and their 
common variants are largely unknown (82).  
The hypocholesterolemic effect of milk in humans has been demonstrated by 
several research studies (76,80,81,83-91).  One study of particular interest, conducted 
by Buonopane, et al. (76), concluded that the daily dietary addition of 1.1 L of 2% 
solids-non-fat fortified skim milk for eight weeks in 64 free-living male and female 
participants was associated with statistically significant reduction in TC levels.  Subjects 
were equally divided into low (<190mg/dL) and high (≥190 mg/dL) baseline TC groups. 
Results demonstrated 5.7% and 6% reductions in TC in the low and high baseline TC 
groups, respectively.  With no variations in other hypercholesterolemic factors, such as 
body weight, the decrease in plasma cholesterol concentration in this study was 
deemed to have been a direct result of the milk consumption.  Study authors believed 
that subject’s compliance to milk supplementation was optimal while the maintenance of 
a stable body weight throughout this study was attributed to a lack of compliance to 
baseline dietary intake patterns.  Dietary intake alterations, specifically calorie and 
nutrient intake variations, were not reported, however statistically significant (2-3%) 
decreases in dietary fat intake were noted in the high cholesterol subject group.  Aside 
from the large quantities of milk consumption in the Mann (81) and Buonopane, et al. 
(76) studies mentioned above, results remain conclusive that within free-living 
populations, milk intake lowers TC values.  However, the exact mechanisms involved in 
this reduction along with the factors in milk responsible for the lowering effect continue 
to remain elusive.   
Effects of fermented milk products on cholesterol reduction.  In order to  
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help distinguish the factor in milk responsible for its cholesterol-lowering property, 
several researchers focused their attention specifically on the cholesterol-reducing 
ability of fermented milk products, including yogurt (78,85, 86,88,89-94).  Human 
studies detailing the link between fermented milk products and cholesterolemia date 
back to the 1970s when Hepner, et al. (85) compared the hypocholesterolemic effect of 
pasteurized and unpasteurized yogurt (three 240-mL portions per week) in a crossover 
trial involving 17 free-living subjects.  Subjects supplemented their daily habitual diet 
with yogurt or 2% milk (720 mL) for four weeks followed by a 4-week washout period 
and reverse consumption.  After a week of receiving unpasteurized yogurt, TC 
concentrations decreased by 5%, but continued on a rising trend following the wash out 
period and milk supplementation.  For the milk first group, plasma TC decreased 
insignificantly, however, following the washout period and one week of yogurt 
supplementation, TC decreased significantly by 9%.  Hepner, et al. (85) conducted a 
similar secondary experiment and supplemented the daily dietary intake of 36 free-living 
individuals with 240 mL of unpasteurized and pasteurized yogurt, containing live 
cultures of L. bulgaricus and S. thermophilus, for 12 weeks.  Study results concluded 
that both yogurt types, unpasteurized and pasteurized, produced decreases in serum 
cholesterol of 9% and 5% respectively.  The authors of this study concluded that milk 
may possess a small hypocholesterolemic effect, which may be mirrored by yogurt.   
In a later study by Agerbaeck, et al. (91), normocholesterolaemic subjects 
supplemented their normal daily dietary intake with 200 mL of fermented milk product.  
Following six weeks of supplementation, the study subjects’ TC and LDL-C 
concentrations were reduced by 6% and 10% respectively.  Milk supplementation has 
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produced a decrease in TC concentrations in several human studies; yet, the 
components of milk with cholesterol-lowering properties have not been adequately 
identified.  Interestingly, the protein fraction of milk may be a likely candidate for inquiry 
rather than the fat content because both skim milk and fermented milk (yogurt) have 
been found to increase HDL-C and lower TC when compared to whole milk (77,85).   
Effect of milk proteins on cholesterol.  A few studies have been conducted to 
ascertain the cholesterol-lowering effects of milk proteins.  Of the major proteins found 
in milk, those found in whey present an interesting avenue for investigation as various 
studies of casein, the primary protein in milk, have resulted in slightly hypercholester-
olemic (animal model) and cholesterol neutral (human model) effects, meaning casein 
produced no effect on cholesterol concentrations when compared to other sources of 
protein (94, 95).  In an animal model, Terpstra, et al. (95) demonstrated that semi-
purified diets containing differing proportions of casein protein (10%, 20%, 40%) fed to 
rabbits over seven weeks compared to a commercial diet feeding regimen resulted in 
elevated serum cholesterol positively correlated with increases in casein protein within 
all groups.  Rabbits fed the commercial diet containing a lower fat and caloric density 
(2,800 kcal/kg feed) consumed a much larger amount of food than those in the semi-
purified diet groups (3,400 kcal/kg feed).  Over the first 4 weeks of the study, the low-
casein diets (10%) produced serum cholesterol and growth rates that were significantly 
lower than high-casein diets (40%).  Within the last 3 weeks of the study, rabbits 
switched from 10% to 40% casein diets exhibited statistically significant increases in 
levels of serum cholesterol with the highest weight gain being observed in this group.  
Throughout the study duration, cholesterol remained constant in the groups receiving 
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the 20% casein and the commercial diets.  Additionally, growth rates and weight gain 
were found to be similar within the 10% and 20% semi-purified diets and none of the 
rabbits exhibited weight loss.  Study findings showed no consistent relationship 
between the rabbit growth rates and levels of serum cholesterol.  Furthermore, study 
conclusions suggested that the formation of whole serum lipoprotein particles relatively 
rich in cholesterol were associated with increasing levels of dietary casein intake.  
In another study, Damasceno, et al. (96) fed 20 rabbits diets containing 27% 
casein compared to 27% soy protein isolate for two months and found that the casein 
feeding contributed to increasing cholesterol concentrations, lipoprotein oxidation and 
aorta atherosclerotic lesions.  In contrast, the soy protein isolate diet, when compared to 
the casein diet significantly decreased cholesterol concentrations, atherosclerotic 
lesions and lipid peroxides of LDL fractions.   
In agreement with these above mentioned studies, Ho, et al. (97) fed swine high 
fat, high cholesterol diets with either casein or soy protein for five weeks and 
documented statistically significant elevated TC levels (334 +/- 46mg/dL) in the casein 
fed group over the soy protein group (122 +/- mg/dl).  In this study, the measured three-
hour lymphatic transport of cholesterol in the casein-fed swine was found to be 
significantly higher than in the soy-fed group and authors concluded that dietary 
proteins likely affect cholesterol transport into the lymphatics.  
In animals, casein ingestion produces a hypercholesterolemic effect, but in 
humans, more cholesterol neutral effects have been documented (98-100).  Sacks, et 
al. (99) studied the cholesterol modifying effect of 27 grams (g) of casein added to the 
daily diet of 13 strict vegetarians who consumed no other form of animal protein during 
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the 40-day study period.  In this study, the casein supplementation produced no 
significant effect on TC or LDL-C concentrations.  In support of these findings, Grundy, 
et al. (100) compared the effects of dietary plant protein (soy) to animal protein (casein) 
intake on plasma lipoproteins in 14 men on a metabolic ward.  Following one month of 
strictly controlled dietary intake of 15% casein protein, 55% carbohydrates, and 30% fat 
(as lard), there was no change in plasma TC or LDL-C concentrations.  These study 
findings support the idea that the cholesterol-lowering component of milk is likely not 
casein.   
Ritzel, et al. (101) chose swine in his controlled feeding study in an attempt to 
examine the effect of large whey protein feedings (57% of the total energy consumed as 
whey protein powder) on serum lipids in animals.  At the conclusion of 112 days, study 
results demonstrated a significant reduction in TC by 6% with the whey feeding.  
Kawasa, et al. (102) supported these findings with the examination of the effect of ad 
libitum feeding of fermented milk supplemented with 80% whey protein concentrate for 
two weeks on the TC in rats.  Study results showed a statistically significant reduction in 
serum TC levels when compared to the control group.  In addition to the rat study, 
Kawasa, et al. (102) also conducted the only study that could be found demonstrating 
the effect of whey protein on cholesterol values in human subjects.  This 8-week study 
examined the consumption of 200 mL of fermented milk supplemented with whey 
protein in 20 healthy adult male subjects.  Although a TC reduction was unreported in 
this study, results showed a statistically significant increase in HDL-C after four weeks 
compared to no change in the placebo group along with a statistically significant 
reduction in subjects’ mean atherogenic index from 4.24 to 3.52.  Overall, the results 
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from these studies point to a possible effect of the whey protein fraction of milk on 
serum lipid levels (101,102).  However, several other mediating factors have been 
proposed, including immunoglobulin G (IgG) (52).   
In an effort to narrow down the true cholesterol-lowering components in milk, 
Golay, et al. (52) and Sharp, et al. (51) reported that the daily administration of 90 g of 
dried skim milk (immune milk from hyper-immunized cows) lowers cholesterol in human 
subjects with mildly elevated cholesterol concentrations. Golay, et al. conducted their 
experiment with immune milk produced from dairy cows hyper-immunized with a 
multivalent bacterial vaccine.  Following an eight-week ingestion of 90 g daily immune 
milk compared to non-immune milk intake (control), a significant reduction in plasma TC 
and LDL-C was demonstrated in mildly hypercholesterolemic human subjects.  Sharp, 
et al. reproduced this study in 30 subjects for 38-weeks and demonstrated similar 
cholesterol reduction results due to immune milk consumption.  The results of this study 
concluded that daily supplementation of an individual’s normal diet with skim milk from 
immunized cows when compared to control milk intake can result in a significant 
reduction of elevated TC and LDL-C concentrations.  In both of these studies, authors 
theorized that the decline in study participant’s cholesterol concentrations could be 
attributed to the immune milk containing higher levels of IgG.  Immune milk may be a 
useful adjunct in the dietary management of hypercholesterolemia due to its higher 
quantity of immunoglobulins; however, the immunoglobulin content of immune milk 
requires further study.  Whereas milk and whey contain 1% and 3-4% globulin protein 
concentration, respectively, immunoglobulin comprises at least 25% of the protein 
content of serum.  
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Immunoglubulins and Cholesterol Reduction 
In an effort to further the research on the cholesterol-lowering effects of 
immunoglobulins, Proliant, Inc., a biotechnology company, has developed a highly 
concentrated immunoprotein-rich product, called ImmunoLin™ (34).  ImmunoLin™ is an 
immunoglobulin-rich isolate extracted from the serum of cattle specifically raised for 
food (34).  The result of this process allows consumers to ingest smaller quantities of 
product with higher levels of immunoglobulin proteins, unlike the impractical intake of 90 
grams of immune milk daily as mentioned in the study above.   
Based on multiple anecdotal reports of cholesterol reduction in consumers 
taking the ImmunoLin™ supplement, Proliant conducted an 8-week, in-house pilot study 
(E Weaver, C Siefken, and R Strohbehn, unpublished observations, 2002).  Eleven 
hypercholesterolemic human subjects (TC > 200 mg/dL, HDL-C < 40 mg/dL) ingested 
5g daily supplementation of ImmunoLin™ for one week.  TC and LDL-C values were 
measured at study initiation, midpoint (4W) and conclusion (8W).  At 8W, participants 
with mild hypercholesterolemia showed a statistically significant TC and LDL-C 
concentration reduction of 15% and 6%, respectively, from baseline.  No formal data 
has been published on the corporation’s study findings.  Blood lipid level reductions in 
these individuals may be attributed to the elevated immunoglobulin protein levels in the 
ImmunoLin™.  In addition, this study suggests that ImmunoLin™ may be useful in the 
management of hypercholesterolemia, specifically TC and LDL-C reduction.  
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Nutritional Supplements and Cholesterol Reduction 
Numerous supplements available on the market today tout heart health benefits along 
with cholesterol reducing ability (103-106).  While supplements are not a substitute for 
proper medical treatment, many individuals turn to natural alternative supplements for 
management of medical conditions.  As many studies support the value of cholesterol 
lowering supplements, some natural supplements have been shown to be beneficial 
adjuncts to dietary modification in controlling cholesterol; therefore, continued 
investigation is necessary (107-109). 
Phytosterols and phytostanols.  Only a few of these researched supplements 
produced statistically significant cholesterol lowering ability in study trials.  Phytosterols, 
naturally occurring plant compounds, are an example of one such supplement that, 
when ingested in conjunction with a low-fat diet, possess the ability to lower the risk of 
coronary heart disease (CHD) via profound reductions in TC and LDL-C (107).  The 
primary mechanism responsible for the cholesterol-reducing activity of phytosterols is 
the inhibition of cholesterol uptake from the intestinal tract in humans (108).  However, 
the actual sites within the intestinal tract where inhibition may occur have not been fully 
elucidated.   
As a food ingredient, phytosterols are generally recognized as safe (GRAS) by 
the U.S. Food and Drug Administration (FDA) and they are found naturally in meat and 
dairy products.  Phytosterols are converted to phytostanols through a commercial 
chemical process called hydrogenation, whereby a liquid vegetable oil is converted to a 
semi-solid or solid form.  Both phytostanols and phytosterols are readily incorporated 
into food products, such as tub margarine spreads (107).  The most common dietary 
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phytosterol is sitostanol (mixtures of soy sterols), a saturated derivative of sitosterol.  In 
a comparison review of three randomized control trials, Law (107) reported a study 
average of 14% LDL-C reduction with a ≥ 2 g dose of plant sterol or stanol per day, 
which equals the amount currently added to an average daily portion of fortified 
margarine.  Additionally, following review of six randomized phytosterol trials, Law 
concluded that cholesterol reduction and decreased incidence of heart disease by one 
quarter with the use of sitostanol-containing spreads was common in all six 
interventions. To further support these findings, Jones, et al. (108) demonstrated a 
statistically significant reduction in LDL-C of 24%, when combined with dietary change, 
in subject’s whose diets were supplemented with 1.7 g of a plant-sterol product 
containing sitostanol as compared to a 9% decrease in the diet-only part of the trial.  
Additional controlled and double-blind trials have confirmed these results (110-113).  
Guggulipid.  Another cholesterol-reducing alternative medicinal therapy, 
guggulipid, derived from an extract of guggul gum, is actually an approved treatment for 
elevated cholesterol concentrations in India (106).  Often referred to by a number of 
names, such as guggul gum, guggul and guggulsterone, guggul is a natural herb whose 
resin is extracted from the Commiphora tree, has been an Ayurvedic medicine 
approach to preventing atherosclerosis for centuries, and has been studied in Eastern 
clinics and hospitals for over 20 years (y).  Two compounds, Z-guggulsterone and E-
guggulsterone, appear to account for guggul’s TC and LDL-C lowering affects and the 
boosting of HDL-C levels.  Urizar, et al. (114) found that guggulsterone, the active agent 
in guggul extract, targets and blocks the activity of the Farnesoid X receptor (FXR), a  
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nuclear hormone receptor present in the liver cells involved in the regulation of 
cholesterol via its function in monitoring levels of bile acids, which are produced from 
cholesterol and released by the liver.  In this study, wild-type and FXR-null mutant mice 
were fed a guggulsterone supplemented high-cholesterol diet for one week and results 
demonstrated a statistically significant decrease in hepatic cholesterol levels in the wild-
type mice that was absent in the FXR-null mice.  However, the mechanism for 
guggulsterone’s effect on the FXR remains unidentified (114).  In another study by 
Singh, et al. (109) researchers reported that the combined effect of a fruit- and 
vegetable-enriched prudent diet with 50 mg of guggulipid capsules taken twice daily for 
24 weeks by 61 hypercholesterolemic individuals produced an 11.7% and 12.5% 
decrease in TC and LDL-C levels, respectively, compared to the pre-diet levels.  The 
TC and LDL-C levels in the placebo group were unchanged.  In this study, the subjects 
were reported to be > 96% compliant to ingestion of the guggulipid capsules.  Final 
study comments noted that, at 36 weeks, the effect of diet and guggulipid was equal to 
that of traditional lipid-lowering drug treatments, however, the subjects‘ final (36-week) 
cholesterol percentage reductions were not reported.   
Red yeast rice.  One of the more promising nutritional supplements, an 
ingredient in red yeast rice, called monocolin K, has been shown to lower cholesterol 
(104,105).  For numerous centuries, red yeast rice has been a component of Chinese 
medicine and a dietary staple in many Asian countries with usual consumption ranging 
from 14 – 55 g per day (0.5 – 2 ounces) (104,115).  Red yeast rice was documented by 
Heber, et al. (115) in a double-blind 12-week clinical trial to lower LDL-C concentrations 
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 by 22% as compared to 1% in the placebo group within 83 men and women with above  
average LDL-C concentrations.  Within this study, the supplemental red yeast rice 
product inhibited the production of cholesterol by halting the action of the primary liver 
enzyme, HMG-CoA reductase, which is responsible for cholesterol synthesis.  These 
authors noted the low cost of red yeast rice supplements in comparison to prescription 
medications, and concluded that this supplement could provide a more cost effective 
and innovative approach to the maintenance of healthy cholesterol concentrations.  
However, since red yeast rice extracts are not pure, meaning they contain additional 
substances, their effects may be less predictable than drug treatments.  
Monacolins, compounds of the statin class, were found to behave similarly to the 
drug, lovastatin, which is currently used for cholesterol-reduction.  Yet, significantly 
lower amounts of the monacolins contained in the red yeast rice were necessary to elicit 
a reduction response comparable to the cholesterol-lowering drug (104,105,115,116).  
However, due to the similarities between statin drugs and the contents in red yeast rice 
supplements, an impending infringement on patent rights was filed resulting in the sale 
of red yeast rice being banned in the United States.  
 
ImmunoLin™ Supplement Product Purity 
Unfortunately, following the conclusion of this study, the first case of a bovine 
spongiform encephalopathy (BSE)-infected cow within the United States food supply 
was documented.  Treatment group subjects became slightly concerned about having 
taken the bovine-derived ImmunoLin™ product.  However, subjects’ questions were  
 
 
           
 
35 
thoroughly addressed and concerns were quelled as they were assured that the 
ImmunoLin™ product was produced under stringent quality control procedures.  In 
addition, subjects were informed that the raw material for the ImmunoLin™ product 
were collected in USDA-inspected facilities and approved for use in food products  
(Appendix D).   
The purification process of Proliant’s ImmunoLin™ product was conducted in a 
closed system, which rigidly insures against product contamination.  The Proliant 
manufacturing facility itself is compliant with FDA Good Manufacturing Practices (GMP) 
for food products, uses only United States beef cattle and cattle less < 30 months of 
age in the production of their product.  Furthermore, Proliant’s ImmunoLin™ product 
was derived from FDA-approved blood products, excluding any brain or spinal tissue.  
These above mentioned measures aid in eliminating any threat of contracting BSE 
(Mad Cow disease) from ingestion of Proliant’s ImmunoLin™ supplement.   
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CHAPTER III* 
MATERIALS AND METHODS 
 This chapter will describe experimental subject selection criteria, method of 
selection, instruments used in measuring experimental variables, experimental 
procedures, and data analysis.  
 
Subjects 
 In this study, 52 men and women aged 25-70 years (y) volunteered for this 
investigation conducted at The Cooper Institute (CI) Center for Human Performance 
and Nutrition Research (Dallas, TX USA). 
 Recruitment.  Individuals were recruited through eligibility screening for 
Cooper Clinic (CC)** employees and the surrounding Dallas/Ft. Worth community in 
person, by word-of-mouth, radio, television and newspaper advertisements  
(Appendix A).   
 Initially, 500 potential participants were screened by phone.  Two hundred and 
fifty eligible participants were qualified based on answers to key questions on the 
medical history questionnaire.  Qualified participants completed medical history, food  
 
∗Part of the data reported in this chapter is reproduced with permission by the American Journal 
 of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition from “Cholesterol-
 lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia” 
 by Earnest CP, Jordan AN, Safir M, Weaver E, Church TS. Am J Clin Nutr 2005;81:792-8. 
 
∗∗ While the CI and CC are both located on the same grounds of the Cooper Aerobics Center 
 campus, they function as fully separate entities. The CI is a non-profit, tax exempt, and public 
 corporation by virtue of its scientific research and professional training/certification endeavors, 
 that operates with its own Board of Trustees and Scientific Advisory Council.  The Institute 
 also maintains financial independence from any other Cooper Aerobic enterprises. 
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frequency and qualities of life questionnaires via an online Internet data collections 
system (Vitalink, Bellevue, WA, USA) or were mailed questionnaires (without Internet 
access) (Appendix B).  Upon completion of the questionnaires, participants provided 
written informed consent approved by The Cooper Institute Institutional Review Board 
and Texas A&M Internal Review Board prior to entering the investigative, blood 
cholesterol-screening portion of the study protocol (Appendix C).  The elapsed time 
between the initial phone screening and the first blood sample was less than two 
weeks. 
 Exclusion criteria.  Participants were excluded from the trial if their plotted 
body mass index (BMI; in kg/m2) was < 18.5 or > 30; they had recently donated blood  
(< 3 months) or failed to agree to donate blood during the trial period; they were 
pregnant, lactating or considering pregnancy during the study period.  Also excluded 
were participants with elevated blood pressure, total cholesterol (TC), low density 
lipoprotein cholesterol (LDL-C) or fasting plasma glucose requiring immediate drug 
therapy according to national guidelines (Joint National Committee on Prevention, 
Detection, Evaluation and Treatment of High Blood Pressure, Adult Treatment Panel II, 
and American Diabetes Association).  Lastly, those individuals who were already taking 
lipid-altering medications, planned to move from the area during the trial, smoked, 
consumed alcoholic beverages exceeding an average of 3 drinks/day (d) or consumed 
coffee > 710 mL/d (in excess of 3 cups/d) were excluded from the study.  Coffee 
drinkers were excluded from this study due to potential impact of coffee intake on TC 
and LDL-C levels (117,118).   
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 Inclusion criteria.  Inclusion criteria for this study necessitated that all  
participants, men and women, possess borderline to undesirable elevated TC ranging 
between 5.44 to 6.99 mmol/L (210 mg/dL to 270 mg/dL), with HDL-C less than 1.81 
mmol/L (70 mg/dL).  In addition, subjects were to be free of cholesterol-lowering 
medications.  If a potential participant was unsure of their TC concentration prior to 
baseline screening, but thought it may be high, these participants were informed of their 
baseline TC concentration so that they could make an informed decision whether to 
enter the trial or seek medical counsel.  In addition, advice was provided to those 
participants with LDL-C > 4.14 mmol/L (160 mg/dL) regarding the risks associated with 
LDL-C concentrations of this nature and these individuals were encouraged to see their 
physician.  If the subject chose to continue participation in the study, a written medical 
clearance from their physician was requested before study initiation.  
Habituated vitamin and/or nutritional supplement users for at least 3 months 
prior to the study inclusion qualified for the study if they were willing to maintain their 
current supplement intake throughout the duration of the study.  All individuals who 
agreed to maintain their current dietary intake and exercise habits were also eligible for 
study participation.  Postmenopausal women, both on and off hormone replacement 
therapy (HRT), were accepted into the study.  Finally, participants on standard medical 
therapy at study initiation (for conditions such as hypertension, arthritis or other chronic 
diseases) were included in the study if they agreed to remain on their current therapy 
throughout trial duration.  All of these variables were examined during the trial via online 
and mail return questionnaires.  A quality of life questionnaire was administered pre- 
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and post-study in order to assess not only the subject’s mood and feelings, but also to 
identify any beneficial supplemental affects on study outcome.   
 Confidentiality.  All subject names remained confidential throughout the 
duration of the study.  An assigned number coding system ensured subject 
confidentiality throughout the study duration.  In addition, group selection or subject 
randomization was computer-generated.   
 Estimated benefits. Subjects taking ImmunoLin™ may have benefited from a 
reduction in serum TC and LDL-C, thereby improving their cardiovascular risk factors.  
In addition, subjects participated in the study without cost and received a complimentary 
copy of their blood lipids and laboratory test results at study conclusion.  Following trial 
completion, each subject was awarded a $100 compensation fee for his or her 
willingness to comply with the daily ingestion of ten capsules and the multiple blood 
collections.  If for any reason a subject was unable to complete the entire eight-week 
study period, full compensation was still awarded for their participation.  After 
completing the trial, any individual assigned to the placebo group received 6 weeks 
worth of the active ImmunoLin™ product to try on their own.  
 Possible risks.  The risks associated with participation in this study were 
nominal (119).  Upon each of the 5 blood draws, subjects may have experienced a 
temporary stinging pain along with the chance of possible bruising at the puncture site 
(119).  To prevent any discomfort and risk, only trained and licensed CI staff 
phlebotomists were responsible for collection of blood samples.  In addition, the study 
was conducted at a medical facility, the CI, with licensed staff nurses and board-
certified physicians on site.  An informational hotline, 972-341-3284, was also 
 
           
 
40 
maintained by the CI’s Principal Investigator and Project Research Director, Dr. Conrad 
Earnest, to answer study participant questions or allow them to report any side effects 
that may have occurred throughout the duration of the study.  
Subjects reported no side effects to the ImmunoLin™ supplement except a small 
amount of weight gain and intolerance to the product delivery system of 10 capsules to 
ingest daily resulting in poor compliance (~75%) to our study treatment.   
 
Survey Instrument 
The food frequency questionnaire (Appendix B) utilized in this study consisted 
of questions concerning the types of foods the study participants consumed throughout 
the duration of the study.  The questionnaire contained a list of food items and required 
participants to indicate whether or not they consumed a particular food by marking the 
average number of times they had eaten that food within the past month, week or day.  
Additionally, to ensure that there were no questions left unanswered on the question-
naire, participants were to record a no response if they did not consume a particular 
food within the month.  
The CI’s food frequency questionnaire was developed using 3-day dietary 
records of individuals from a similar study population (120).  The questionnaire was 
specifically designed to focus on five key dietary components, including energy and fat 
intake.  Non-quantitative portion sizes, based on the USDA standard portion size 
amounts for common foods, were used to estimate the amounts of particular foods 
recorded as consumed (121).  Because these portion sizes are only estimates of the 
exact amounts actually eaten, this type of food frequency questionnaire is most 
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effective for estimating intake amounts for key dietary components across a group of 
individuals versus for measuring individual dietary intake (122). 
Food frequency questionnaires were administered at baseline and at 6 weeks 
(W) to examine total energy intake and macronutrient partitioning.  Following 
completion of the questionnaires, each was computer-scanned.  Based on subject 
question responses, summary dietary information was generated for total energy, fat 
(including the different types), cholesterol, and alcohol using the Food Intake Analysis 
System (FIAS; version 3.9, Human Nutrition Center, University of Texas Health Science 
Center School of Public Health, San Antonio).  The FIAS system was selected for this 
study because it is linked with the Pyramid Serving Database (PSDB) (123).  The USDA 
food codes generated after analysis of the dietary recalls in FIAS are correlated with 
PSDB to determine the number of servings of each of the major food groups consumed 
by study participants.  The database was developed to analyze the number of servings 
in each of the Food Guide Pyramid’s major food groups, including the amounts of 
discretionary fat and sugars consumed (124).  Results from the study food frequency 
questionnaires are reproducible, valid and reliable (122).        
 
Pre-Trial Screening and Baseline Testing 
A four-phase approach was utilized in performing this trial.  These phases 
included a telephone screening procedure to determine potential eligibility; three 
baseline visits, inclusive of two run-in screening visits; 6 weeks (W) of treatment, 
inclusive of a 3W mid-study visit; and a post-test assessment.  A general schematic of 
the trial is presented in Figure 1. 
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During the first phase of the trial, 500 potential participants were screened by 
telephone resulting in 250 individuals who were qualified to begin the baseline-testing 
portion of the trial.  Once participants were determined eligible to continue the trial, 
during this second phase, each participant was requested to participate in three 
baseline visits prior to formal randomization into the trial.  During the first two visits of 
this testing phase, each subject participated in two run-in visits within 7 days of each 
other.  Successful continuation to the third baseline visit was predicated on obtaining 
two TC concentrations differing by ≤ 10%.  If the TC difference between these two visits 
was > 10%, a requested third baseline measurement was performed.  Averages of the 
two closest baseline measures were accepted for the entry criterion lipid variable.  
Following this run-in procedure, 90 participants remained eligible to continue to the third 
baseline visit of the trial where blood collection was performed to examine other blood 
markers using a basic blood chemistry panel (Chem-16) measuring 16 variables 
associated with alterations in hepatorenal or cardiovascular function. 
 
 
 
  
Blood cholesterol run-in, paperwork, and 
two blood draws, 7-10 d apart. A third draw 
if cholesterol variance >10% 
 
   Figure 1. Schematic representation of study timeline. bIg, bovine serum immunoglobulin. 
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In conjunction with the third baseline visit, each participant was required to 
complete several questionnaires detailing their medical history and dietary habits.  
These questionnaires were made available via an online Internet data collection system 
(Vital Link, Bellevue, WA, USA).  Questionnaires were mailed to those participants 
without Internet access.  Once participants completed all forms and the three baseline 
visits, they became eligible for formal random assignment into the treatment portion of 
the trial.  If these conditions were not met, the participant was not randomized into the 
treatment portion of the study.  The time elapsed between the first run-in visit and the 
third baseline collection period ranged from 10 to 12 days. 
The rationale for using this type of enrollment procedure was to establish stable 
baseline entry criteria for TC, as well as attempt to minimize dropouts and maximize 
protocol compliance by dissuading participants who were less likely to complete the trial 
given their low willingness to adhere to the study procedure.  Of the 90 participants 
eligible for random assignment, 10 withdrew prior to randomization due to “lack of 
continued interest” in pursuing the study and 24 failed to complete all baseline visits 
and/or necessary paperwork.  Thus 56 participants received formal random assignment 
randomized to undergo treatment and enter the third phase of the study, i.e. the 
treatment phase. 
 
Treatment and Assessment Indices 
The treatment source of bIg utilized in this study is an immunoglobulin-enriched 
serum protein fraction obtained through the partial removal of fibrinogen, lipids and 
albumin.  The resulting total protein fraction was 88.6%, with the remainder of the 
chemical constituents being moisture (< 8%) and ash (< 3%). The total IgG was 48.4% 
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as determined by radial immunodiffusion assay.  Proliant’s ImmunoLin™ treatment was 
obtained from the plasma of USDA inspected and approved beef cattle raised for food 
that were < 30 months of age, purified by membrane filtration and spray dried.  
Hydrolyzed gelatin, a cholesterol-free, GRAS protein source was utilized as the source 
of protein for the control group as it was a cost-effective and easily manufactured 
treatment option (125). All treatment bottles and capsules were distributed using 
identical bottles, size and coloring via a randomized number sequence for treatment 
distribution so that in the case of side effects, the treatment code of that particular 
individual could be broken rather than sacrifice the integrity of the entire treatment 
group.  One of the investigators was in charge of this aspect of the study (ANJ) and had 
no contact with any of the study participants at anytime nor was involved in the data 
analysis process.  
During this third trial phase, each participant was randomly assigned, in a 
double-blind manner, to consume ten treatment (bIg) or placebo capsules, containing   
5 g of the appropriate treatment, daily (5 capsules; BID) for 6 W and verbally instructed 
to take them with a meal (5 capsules in the morning, 5 capsules at lunch or dinner with 
the latter being their choice).  The 10 capsule treatment regimen provided 5 g of 
Proliant’s ImmunoLin™ per day (34).  The ImmunoLin™, treatment dosage amount for 
this study was determined based on Proliant’s in-house pilot data showing this amount 
to be efficacious (unpublished study results, Proliant Inc. 2002).  Additionally, due to the 
use of capsules, the possibility of using a larger dosage was prohibitive.  Subsequently, 
the sample size for this trial was chosen on the basis of power calculations obtained 
from this pilot effort.   
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Given that this was a study using a “free living” population, and recognizing the 
fact that alterations in body mass and energy intake can affect cholesterol 
concentrations, participants were weighed and food frequency questionnaires were 
collected before (baseline) and following (6W) study intervention (fourth phase of the 
trial) to examine total energy intake and macronutrient partitioning.  At trial initiation, 
3W, and trial close (6W) all participants were questioned about noted side effects and 
encouraged to report any noticed side effects throughout the 6-week study duration.  
Additionally, all participants agreed to maintain their current dietary intake and exercise 
habits and to avoid beginning the consumption of any new supplement or medication.  
At study initiation, participants received enough capsules for 3W worth of 
treatment (bIg) or placebo.  All participants were requested to return at the 3W study 
interval for interim blood measurement and determination of capsule compliance by pill 
count.  Following the 3W visit, new bottles were provided to study participants with 
enough treatment or placebo capsules to complete the trial (6W).  Upon return of all 
study participants at 6W, a final pill count was performed.   
The validity of pill counting may be affected by loss of pills or fabrication of pill 
ingestion, both of which can result in overestimation of treatment intake (126,127).  
However, the pill count method is still one of the most common methods used in 
assessing medication compliance instead of self-reported pill ingestion via patient 
interview, which has been regarded as unreliable for accurately assessing adherence to 
a medical regime (126,127).  Unfortunately, there appear to be no viable alternatives to 
this method of obtaining data on medication compliance.  
Blood was obtained in a fasting condition (> 12 hours) at pretrial, 3W and 6W for 
several analyses, including a blood lipid profile, blood glucose concentration, and 
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muscle, kidney, and hepatorenal indexes (Chem-16).  At blood collection, ≈ 50 mL of 
blood were divided into one serum separator evacuated tube (10 mL) and four K3 
EDTA-coated tubes (≈ 40 mL).  Licensed CI staff phlebotomists drew the blood for this 
study.  Subsequently, all blood samples were spun within 3 minutes of venous 
collection in a cold centrifuge at 2383 x g for 15 minutes at 4°C (Celsius).  Separated 
plasma and red blood cells were divided into four cryovials and placed in –80 °C 
freezers.   
Blood lipid profiles, fasting blood glucose concentration, and muscle and 
hepatorenal indices were analyzed at a commercial laboratory, (Lab Corp, Dallas, TX 
USA).  The Friedewald formula (128) was utilized to calculate LDL-C, where LDL-C = 
[TC – (HDL-C + TG/5)].  In order to validate the use of an external laboratory, where 
minor differences in cholesterol may be related to the time of day of the analysis, 
changing technicians and/or different reagents used over the course of the clinical trial, 
40 frozen blood samples were randomly chosen for a reliability analysis and sent to an 
alternate laboratory.  These samples were tested in batch on the same day.  The results 
of this secondary sample analysis showed no difference in TC or LDL-C with the data 
obtained from LabCorp (CV = 0.08; r2 = 0.96) subsequently utilized in this study report.  
 
Statistical Analysis 
The primary outcome variables examined in this trial were TC and LDL-C.  All 
other lipid sub-fractions inclusive of very low density lipoprotein cholesterol (VLDL-C), 
HDL-C and TG were treated as secondary outcome measurements.  As tertiary 
measures, blood glucose and the Chem-16 panel were examined.  All baseline, primary 
and secondary outcome measurements were examined for normal distribution 
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characteristics.  As such, each variable was found to be normally distributed; thus, data 
were not adjusted.   
In order to examine potential treatment differences in this study, primary, 
secondary, and tertiary variables were examined separately using a repeated measures 
multivariate analysis of covariance (MANCOVA), covaried for a change in total energy 
expenditure and alcohol intake for both groups (see below) with the use of a 3-step 
approach.  First, an initial MANCOVA was performed to determine the overall time 
effects and treatment time-by-treatment interaction for statistical significance.  
Secondly, if a significant statistical or interaction effect was observed for the overall 
MANCOVA, changes in individual lipid variables were examined by treatment effect at 
each time point (i.e. baseline, 3W and 6W).  Thirdly, a Tukey-Kramer post-hoc test was 
used to examine appropriate within or between group changes at 3W and 6W.  All food 
frequency data was assessed using a 2 x 2 analysis of variance (ANOVA) to denote 
before and after and between- and within-group food values.  All statistical analyses 
were performed using JMP statistical software (version 5.0.1.2; SAS Inc, Cary, NC) 
Statistical significance referred to a P value of < 0.05.  All data were reported as mean ± 
SD.  
In an attempt to clarify the affect of food intake on changes in the lipid 
characteristics, several regression analyses of food intake a posteriori were performed 
(APPENDIX E).  However, these interpretations must be considered with caution as the 
use of repeated regression analyses on co-related variables increases the likelihood of 
inflating the experiment-wise error rate of the study and decreasing the likelihood of 
detecting a true statistical relationship when one does not exist (i.e., Type I error). 
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CHAPTER IV∗ 
RESULTS 
Results 
 Study population demographics and compliance analyses.  After formal 
randomization to the treatment phase of this study protocol (N = 56), four participants 
dropped out of the study.  These individuals were equally distributed between the 
placebo and treatment groups.  Three of these individuals (2 and 1 in the placebo and 
bIg groups, respectively) dropped out prior to the 3W visit.  Two of these dropouts cited 
daily capsule number intake as the reason for stopping the study.  One participant 
asked to drop out because, “the treatment made her feel drowsy.”  However, after 
breaking this subject’s treatment code, it was determined that she was in the placebo 
group.  The one treatment participant continuing past the 3W visit dropped out due to 
an unexpected job move to a different state.  As three of the randomized participants 
did not attend the 3W visit, the authors of this study elected not to perform an intent-to-
treat analysis.  This decision was based on the observation that inclusion of these three 
subjects and/or the one participant that surpassed the 3W visit would not alter study 
outcome or any data reported below.   
No differences for age, body mass index (BMI) or any lipid variable were evident 
in this study population.  The mean (±SD) age of study participants was 51 ± 8.2 years 
(y).  Baseline body mass was 79.96 ± 10.2 kg.  The treatment (bIg) group was 
comprised of 16 men and 10 women and the placebo group consisted of 15 men and  
∗Part of the data reported in this chapter is reproduced with permission by the American Journal 
 of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition from “Cholesterol-
 lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia” 
 by Earnest CP, Jordan AN, Safir M, Weaver E, Church TS. Am J Clin Nutr 2005;81:792-8. 
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11 women.  No gender interactions for any of the subsequent treatment analyses were 
observed in this study.  Throughout the study, each group remained ~75% compliant to  
the study protocol, citing daily pill ingestion number as the primary reason for lack of 
compliance.  No difference in compliance between the treatment (78%) and placebo 
group (73%) was observed (P = 0.33).  However, a significant main effect of time 
(P<0.01) on total energy consumption was observed for both study groups, 
demonstrating a decrease in total energy consumption during the study period.   
Energy partitioning and macronutrient analyses.  A description of this study 
population’s macronutrient energy partitioning is presented in Table 6.  Analysis of 
individual macronutrients showed no other significant difference between the treatment 
and the control group findings other than the main effect for time (P < 0.01) and related 
decrease in total energy consumption noted above.  These included carbohydrates, 
protein, total fat, and associated subfractions of fat (saturated, polyunsaturated, or 
monounsaturated fat), dietary cholesterol and dietary fiber.  A significant main effect of 
time with regard to alcohol intake (P < 0.01) was also observed.  A decline in alcohol 
intake may be attributed to limitations of self-reported food intake data, or possibly a 
concern by study participants that alcohol intake might interfere with treatment efficacy 
(121).   
Changes in dietary behaviors, as measured by food frequency intake records, 
were noted in each study group with profound variations occurring in the placebo versus 
the treatment group from baseline to study conclusion.  However, despite performing a 
regression analysis in an attempt to clarify the affect of food intake on changes in lipid 
characteristics, only weak, yet statistically significant findings, summarized as LDL-C 
decreases for increases in protein, fat, carbohydrates and dietary cholesterol intake, for 
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the treatment group only were observed.  And, it is contradictory for increases in these 
variables, specifically dietary cholesterol and fat intake, which largely contribute to 
raising cholesterol levels, to be related to declines in LDL-C values.   
 
 
 
 Treatment (n = 26) Placebo (n = 26) 
Nutrient Intake Baseline Week 6 Baseline Week 6 
 Total Energy (kJ • d-1)2 7862 ± 3472.4 6814 ± 1968.2 7644 ± 2784.1 6459 ± 3548.9
 Protein (g • d-1) 77.70 ± 41.3 70.50 ± 47.4 84.40 ± 62.2 62.20 ± 40.8 
 Carbohydrates (g • d-1) 223.80 ± 110.6 199.7 ± 96.9 235.60 ± 146.3 195.30 ± 133.6
 Fat Intake (g • d-1)         
Total Fat 70.70 ± 38.8 67.2 ± 50.5 74.80 ± 55.1 56.90 ± 38.8 
Saturated Fat 23.2 ± 12.7 21.60 ± 16.8 25.00 ± 20.4 18.60 ± 12.7 
MUFA 26.8 ± 14.8  25.90 ± 19.4 28.40 ± 21.4 21.50 ± 14.8 
PUFA 15.10 ± 8.7  14.60 ± 10.2 15.00 ± 10.2 12.10 ± 8.7 
 Cholesterol (mg • d-1) 264.30 ± 189.2 221.70 ± 158.1 273.40 ± 262.1 193.20 ± 139.7
 Alcohol (g • d-1)2 10.50 ± 27.5 4.91 ± 7.1 8.10 ± 12.2 5.91 ± 7.6 
 Fiber (g • d-1) 18.10 ± 8.7 16.40 ± 7.6 20.10 ± 13.8 16.10 ± 12.7 
         
1 All values are x ± SD. MUFA, monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. 
2 Significant main effect for time P < 0.001 (ANOVA). There were no other significant main 
   effects as interactions. 
   
 
 
 
Furthermore, emerging research has shown a relationship between body weight 
and milk intake (129,130), as well as potentially influencing lipid outcomes; the subjects’ 
dietary milk intake was examined.  No between or within group differences for total milk 
intake, low fat intake (< 2% fat) and high fat milk intake (≥ 2%) were found.  Total milk  
 
Table 6 
Nutrient characteristics for the study cohort during the experimental period1 
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intake ranged between 0.20L and 0.43L servings (227 mL each) per day for both the 
placebo and treatment groups.  
 Primary lipid variables.  With repeated measure MANCOVA analysis, a 
statistically significant overall main effect of time (P < 0.001), treatment (P < 0.03) and 
time-by-treatment interaction (P < 0.0001) was observed.  Subsequently, each lipid 
variable was examined individually, and both TC and LDL-C were found to be 
statistically significant for time and treatment at 3W and 6W (both: P < 0.0001).  At 6W, 
statistically significant between group differences were observed for TC (P < 0.005) and 
LDL-C (P < 0.007).  Based on these results, a Tukey post-hoc assessment of TC and 
LDL-C for the within (i.e., time) group effects observed at 3W and 6W was performed.  
However, only the between group effects at 6W were examined as no statistically 
significant treatment effect was noted at 3W.  The results of this analysis are fully 
detailed in Table 7.   
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Lipid Characteristics Treatment (n = 26) Placebo (n = 26) 
 Total cholesterol (mmol/L)2-4     
Baseline 6.33 ± 0.1 6.16 ± 0.1 
3-week change3 5.98 ± 0.55 6.13 ± 0.6 
6-week change3,4 5.97 ± 0.75,6 6.06 ± 0.5 
 LDL cholesterol (mmol/L)2     
Baseline 4.12 ± 0.6 3.95 ± 0.5 
3-week change3 3.92 ± 0.75 4.00 ± 0.6 
6-week change3,7 3.84 ± 0.65,6 3.92 ± 0.6 
 HDL cholesterol (mmol/L)     
Baseline 1.35 ± 0.05 1.49 ± 0.04 
3-week change 1.28 ± 0.3 1.46 ± 0.3 
6-week change 1.29 ± 0.3 1.52 ± 0.3 
 VLDL cholesterol (mmol/L)     
Baseline 0.87 ± 0.5 0.71 ± 0.3 
3-week change 0.78 ± 0.4 0.73 ± 0.3 
6-week change 0.84 ± 0.5 0.62 ± 0.2 
 Triglycerides (mmol/L)     
Baseline 1.84 ± 0.9 1.51 ± 0.6 
3-week change 1.65 ± 0.8 1.43 ± 0.7 
6-week change 1.77 ± 1.0 1.35 ± 0.8 
   
1 All values are x ± SD. 
2 Significant overall main effects of time (P < 0.001) and treatment (P < 0.03) and 
   significant time × treatment interaction (P < 0.0001) (repeated-measures multi- 
   variate analysis of covariance). 
3 Statistically significant for time × treatment interaction (both: P < 0.0001)  
4,7 Statistically significant for time × treatment (i.e., between-group interaction):       
     4P <  0.005, 7P < 0.007 
5 Significant within-group (i.e. time) difference from baseline group, P < 0.05 (Tukey- 
   Kramer post hoc analysis). 
6 Significantly different from placebo P < 0.05 (Tukey-Kramer post hoc analysis). 
 
 
 
Table 7 
Serum lipid characteristics of groups during the experimental period1 
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Overall, post-hoc assessment demonstrated a statistically significant within 
treatment group reduction in TC from baseline to 3W (-0.35 ± 0.5 mmol/L, P < 0.05) and 
6W (-0.36 ± 0.6 mmol/L, P < 0.05).  By 6W, the reduction in TC from baseline was 
statistically significantly different from that in the placebo group (P < 0.05).  No statistically 
significant within group difference from baseline for the placebo group at 3W (-0.03 ± 0.5 
mmol/L) or 6W (-0.10 ± 0.4 mmol/L) was observed.  Mean change data in TC and LDL-C 
during the 3W and 6W intervals for the treatment and the placebo groups are detailed in 
Figures 2a and 2b with error bars representing 95% confidence intervals. 
 
 
 
 
Figure 2a. Mean change data for TC (mmol/L) in study cohorts. Data analysis via 
repeated measures MANCOVA is co-varied for change in total energy and alcohol intake with Tukey 
post-hoc assessment following significant parameter estimates. Level of significant at P < 0.05 for 
within group analysis vs. baseline is denoted by * symbol. Significant difference between treatment 
and placebo groups (P < 0.05) is represented by ** symbol.  
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The observed reduction in TC could be attributed to the statistically significant 
reduction in LDL-C subfraction, where a significant within treatment group reduction from 
baseline in LDL-C at 3W (-0.20 ± 0.3 mmol/L; P < 0.05) and 6W (-0.28 ± 0.4 mmol/L; P < 
0.05) was found.  By 6W, a statistically significant difference between groups was  
observed, whereby the Tukey post-hoc examinations showed LDL-C to be significantly 
lower in the treatment group than in the placebo group (P < 0.05).  No within-group 
Figure 2b. Mean change data for LDL-C (mmol/L) in study cohorts. Data analysis via 
repeated measures MANCOVA is co-varied for change in total energy and alcohol intake with Tukey 
post-hoc assessment following significant parameter estimates. Level of significant at P < 0.05 for 
within group analysis vs. baseline is denoted by * symbol. Significant difference between treatment 
and placebo groups (P < 0.05) is represented by ** symbol.  
 
 
           
 
56 
treatment differences from baseline were observed in the placebo group at 3W (0.05 ± 0.4 
mmol/L) or 6W (-0.03 ± 0.4).   
 Secondary lipid parameters and tertiary outcomes analysis.  An 
examination of these data (i.e. HDL-C, VLDL-C and TG) revealed statistically significant 
main effects or time (P < 0.001), treatment (P < 0.0001) and the time-by-treatment 
interaction (P < 0.001).  However, despite this overall MANCOVA result, no other 
statistically significant results for the marker estimates associated for HDL-C, VLDL-C, 
TG or glucose were found.  Furthermore, no significant changes in other blood 
chemistry markers associated with hepatorenal or cardiovascular function were seen.  
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CHAPTER V∗ 
GENERAL DISCUSSION AND CONCLUSION 
Bovine Immunoglobulin Lowers Cholesterol 
The primary purpose of this experiment was to assess the cholesterol-lowering 
properties of a bovine immunoglobulin (bIg)-rich supplement on blood lipids, mainly total 
cholesterol (TC) and low density lipoprotein cholesterol (LDL-C), in a cohort of hyper-
cholesterolemic human subjects.  This chapter will discuss the outcomes of our study in 
relation to our hypotheses.  
Hypothesis one.  The first hypothesis of this study was there would be a 
statistically significant reduction in TC and LDL-C in the treatment group compared to 
the placebo group.  By 6W, the reduction in TC from baseline in the treatment group 
was statistically different from that in the placebo group.  No significant within-group 
differences in the placebo group from baseline to 3W or 6W were observed.  However, 
because a reduction in TC and LDL-C occurred within the control group, it was specu-
lated that this finding could be due to variations in single cholesterol measurements or 
the placebo effect within the control group.  As normal physiologic variations can occur 
in cholesterol measurements simply due to such variables as stress or posture, these 
variables could account for the change in the placebo cholesterol concentrations (131).   
The second plausible explanation for the cholesterol variations in the placebo 
group may be attributed to what is called the “placebo effect”, whereby a medical 
improvement is seen in relation to no treatment (132-134).  The placebo effect has been  
∗Part of the data reported in this chapter is reproduced with permission by the American Journal 
 of Clinical Nutrition. © Am J Clin Nutr. American Society for Clinical Nutrition from “Cholesterol-
 lowering effects of bovine serum immunoglobulin in participants with mild hypercholesterolemia” 
 by Earnest CP, Jordan AN, Safir M, Weaver E, Church TS. Am J Clin Nutr 2005;81:792-8. 
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documented in a variety of study conditions, including mortality in coronary artery 
disease (CAD) (134).  One study of a lipid-lowering drug in coronary heart disease 
(CHD) patients demonstrated that subjects taking the placebo, who were only 80% 
compliant with pill intake, had a reduction in mortality rate of 28.3% after 5 years when 
compared with a 15.1% mortality rate reduction for subjects who were compliant with 
placebo intake (135).  In another study, Horowitz, et al. (136) found that patients with 
CAD who were noncompliant with placebo intake experienced two-fold higher death 
rates than those subjects who were compliant with their placebo pill intake.  These 
studies demonstrate that the placebo effect can have clinical consequences.   
The third plausible explanation for changes in cholesterol within the placebo 
group could be attributed to the dietary changes, specifically the reduction in dietary TC, 
total fat, and saturated fat intake.  Though a thorough analysis of data was performed, 
the reason for noted changes in reported dietary behaviors was not found.  The placebo 
hydrolyzed gelatin capsules might have triggered a decrease in appetite or an increase 
in fluid consumption, resulting in a decline in total food intake, however no studies could 
be found to document this hypothesis.  
 Statistically significant reductions were observed in blood lipids, mainly TC and 
LDL-C, within treatment group subjects.  The fraction of cholesterol most associated 
with the TC change was LDL-C, though, minor variations in HDL-C may account for part 
of the observation despite lack of statistical significance at 6W. 
 Hypothesis two.  The second hypothesis was that following an 8-week 
ingestion of 5 g daily of ImmunoLin™, TC and LDL-C concentrations would be reduced 
by at least 8 to 10% in hypercholesterolemic human study participants.  Results 
demonstrated a 5.8% and 6.8% reduction in TC and LDL-C respectively within the 
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experimental group at trial completion.  Despite the statistically significant reductions 
observed, they did not meet the required percentage to prove the hypothesis of an 8 to 
10% reduction in TC and LDL-C nor match Proliant’s pilot study results of a 15% 
reduction in TC.  Some explanations accounting for differences in percent reductions 
between this research study and the Proliant pilot study could be the following: sample 
size, treatment compliance, HDL-C baseline values, and a “threshold effect” theory.  
The unpublished Proliant study contained only 11 treatment subjects with TC 
within the 5.44 to 6.99 mmol/L (210 mg/dL to 270 mg/dL) versus the 52 subjects in this 
study.  The smaller sample size in the Proliant study may account for inflated 
cholesterol percentage reductions and may not be representative of the general 
population as larger sample sizes generally result in increased study reliability.  Aside 
from sample size, treatment compliance may also have produced variations in results.   
Throughout this research, each group remained ~75 % compliant to the study 
protocol as measured by pill counting.  Threats to validity of pill counting include loss of 
pills or fabrication of pill ingestion, which can result in overestimation of treatment 
compliance.  An alternate method used in assessing medication (pill) compliance is self-
reported pill ingestion.  However, as previously noted, self-reported compliance 
information is also characterized by potential threats in validity (126).  Despite the 
validity threat associated with pill counting, it remains as one of the most common 
methods utilized in medication compliance studies (126).  However, subjects did cite pill 
ingestion number as the primary reason for lack of compliance.   
The subject’s mean HDL-C levels in this study were 13 points lower than 
subject’s values in the Proliant study, which resulted in higher LDL-C baseline values in 
the Proliant study subjects.  Speculation is that the bIg supplement affects TC values 
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mostly through reducing LDL-C as demonstrated by the lack of statistically significant 
variations in HDL-C or VLDL-C observed in this study.  If the LDL-C values in the 
Proliant study were indeed higher due to the lower HDL-C levels, one would expect 
greater reductions in TC, as noted in the Proliant study.   
Another possible explanation for greater effects seen in the Proliant study may 
be due in part to a “threshold effect,“ meaning LDL-C must be above or at a certain 
“threshold” to see a supplement effect on cholesterol reduction (137).  With subjects in 
the Proliant study having higher LDL-C values, potentially above or equal to this study’s 
proposed threshold value, reductions observed in LDL-C in the Proliant study may have 
potentially been greater than in this study, however further research would be 
necessary to potentially elucidate this supposition.  This research found that the 
greatest change within the treatment group occurred at the 3W period for TC and LDL-
C, with results demonstrating a 5.5% and 4.9% reduction, respectively.  At the 6W 
interval, there was only an additional 0.3% and 1.9% reduction in TC and LDL-C, 
respectively, despite the additional 3W of treatment.  Additionally, a statistically 
significant reduction in VLDL-C of 10% at the 3W interval was observed within the 
treatment group, however, the percent change for VLDL-C at the 6W interval was not 
statistically significant.  These results support a “leveling off” supposition, whereby when 
LDL-C levels fall below the “threshold” as mentioned earlier, reductions in cholesterol 
gradually begin to plateau as noted at the 6W conclusion of this study.   
Immunoglobulins.  Milk constituents, such as immunoglobulin G (52), mag-
nesium (76), riboflavin (76), orotic acid (76), and an unknown inhibitory factor (81) have 
all been proposed as potential mediators of cholesterol reduction.  Additionally, declines 
in cholesterol have been attributed to increased bacterial gut activity (138).  The major 
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constituents of milk that can be eliminated as potential cholesterol-lowering mediators 
(given their hypercholesterolemic nature) include saturated fat, lactose, calcium, and 
casein (139).  
In support of the immunoglobulins being responsible for the decline in 
cholesterol concentrations, Golay et al. (52) compared the daily intake of 2 L standard 
skim milk with skim milk from immunized cows for in 11 male subjects with primary 
hypercholesterolemia for 8 weeks.  Subject’s dietary intake composition remained 
unchanged throughout the duration of the study.  Though small sample size may limit 
outcome reliability, the researchers found a TC and LDL-C reduction of 8% and 4%, 
respectively.  Because immune milk differs from standard milk in immunoglobulin 
content, study researchers speculated that the increased immunoglobulin amounts 
found in immune milk were responsible for the cholesterol-reduction.  Additionally, the 
authors directly attributed reductions in TC concentrations to the increased specific 
activity of the milk immunoglobulin G fraction against human gut microorganisms, which 
they proposed potentially, may alter cholesterol metabolism within the intestinal micro-
flora.  However, a factor that complicates comparing this research to previous studies 
involving immune milk is the observation that the bIg protein concentrations used in 
these previous studies involving immune milk products are unknown.   
The amount of immunoglobulin necessary to produce a lipid-lowering effect, 
specifically 5.8% for TC, in this study was 2.4 g/day.  These results are similar to the 
results observed in a human study using an immune milk product that achieved a 6.6% 
reduction in TC, while subjects consumed only 0.5 g of bIg/day (51,52).  In light of these 
similarities, one can infer that greater intake amounts of bIg may not necessarily equate 
to higher reductions in TC.  Additional studies will be necessary to determine the opti-
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mum level of supplementation of bIg to produce a desirable cholesterol-lowering effect.  
The effects of bIg supplementation reported in this study may point to a means of 
modulating circulating cholesterol such as with previous dietary approaches focusing on 
phytosterols, soluble fiber, or soy protein, which affect intestinal cholesterol absorption.  
In conclusion, Proliant’s ImmunoLin™ product positively impacted cholesterol profiles in 
hypercholesterolemic human subjects and further investigation into its use is warranted.   
 Bovine immunoglobulins and cholesterol reduction mechanisms.  Current- 
ly, the exact mechanism of action for the bIg lipid lowering effect is unknown.  However, 
several previous research findings provide insight into potential mechanisms, including 
the lipogenic effects of endotoxin and cytokines (140) and factors in plasma, such as 
plasma apolipoproteins, which may affect cholesterol absorption (141,142).  The bIg 
utilized in this study was reported by Proliant, Inc. to contain minimal amounts of  
endotoxin and cytokines based on pre-tested Standard Plate Count (SPC) results of  
< 1000/ mL (personal conversation with Dr. Eric Weaver, vice president and manager of 
scientific research and development for Proliant, Inc.).  SPC results should be < 10,000/ 
mL.  The exact amounts of endotoxin and cytokine content within the ImmunoLin™ 
product were not measured in this study.   
Data on the effects of feeding plasma protein components on cholesterol 
metabolism is scarce.  The only previously reported animal study to evaluate the effects 
of plasma protein components on cholesterol absorption or metabolism found no 
differences in serum or liver cholesterol concentrations between animals fed soy protein 
and plasma protein, whereas significant increases in liver cholesterol concentration was 
reported for casein (94).  However, bIg is not absorbed in the gut of healthy adults so its 
effects are mostly luminal.  A luminal effect is possible since intestinal cholesterol 
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absorption is an important origin of circulating LDL-C (143,144).  Cholesterol enters the 
lumen of the small bowel via the diet and directly from biliary cholesterol excretion.  
Intestinal cholesterol undergoes micellar adaptation by bile salts and is absorbed into 
intestinal cells whereby it is esterified via acyl coenzyme A cholesterol acyl transferase 
(ACAT), packaged into chylomicrons within the intestinal epithelial cell, and transported 
through the lymphatic system to the liver (142,143).   
Endotoxin, a pro-inflammatory molecule produced by immune cells in the gut, 
has been shown to be lipogenic and is proposed to be a contributor to atherosclerosis 
and cardiovascular disease because of its pro-inflammatory effects (145).  Oral    
administration of bIg may possess gut endotoxin-binding capacity because it contains 
endotoxin-binding proteins.  Endotoxin-mediated lipogenesis was found in animal 
models to be mediated via increased activity of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase (HMG-CoA reductase) and reduced cholesterol 7-alpha-hydroxykase activity 
(146-149).  Interestingly, immunoglobulin and other plasma proteins possess an 
endotoxin-binding capacity which when administered orally in sufficient quantity have 
the potential to bind endotoxin in the lumen and subsequently affect inflammatory 
cytokine production in the intestine (150).  Helping to substantiate this premise is the 
finding that the oral administration of an IgA-bIg fraction of human plasma affects 
inflammatory cytokine production (151).  Antibodies and other plasma proteins may also 
be involved in reducing cholesterol absorption.  Antibodies to cholesterol were present 
in normal human and animal plasma (143,152).  It is unknown whether antibodies to 
cholesterol were present in the study treatment (bIg) protocol and this was not 
evaluated.  However, if present, these antibodies may directly bind cholesterol in the 
lumen and hinder absorption.  At this time, no known studies exist that directly link oral 
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bIg intake and endotoxin effects.  Future studies are necessary to elucidate the exact 
mechanism of action for bIg on endotoxin binding capacity.      
 
Concluding Remarks 
An immunoglobulin effect, as evidence by a statistically significant reduction in 
TC and LDL-C reductions within the treatment and placebo group was observed in this 
study.  Furthermore, despite the possible threshold and leveling effect of LDL-C reduc- 
tion within the treatment group, it is speculated that the ImmunoLin™ product positively 
impacted the subject’s TC values and CHD risk (153).  In addition, if a follow-up study 
were conducted with better control for HDL-C values, a greater LDL-C reduction effect 
may have been observed.  In retrospect, this study may also have shown a greater 
immuno-globulin related cholesterol lowering effect via modifying the delivery system of 
the treatment product as treatment compliance was minimized by the need for the large 
quantity of daily pill ingestion.   
This research demonstrated that the ImmunoLin™ had a cholesterol lowering 
effect that may be a useful adjunct combined with or in lieu of medications for 
individuals who are intolerant to drug side effects.  In addition, more dramatic results 
may be obtained utilizing ImmunoLin™ in conjunction with lifestyle modifications, 
specifically diet and exercise, so individuals may be able to avoid or prolong the need 
for cholesterol medication; assessing this combination is worthy of future study.  In view 
of the size of the hypercholesterolemia problem in industrialized countries, the results 
observed in his research should encourage further studies of the effects of globulin 
protein supplementation on cholesterol metabolism in humans. 
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CHOLESTEROL RESEARCH AT  
THE COOPER INSTITUTE 
 
The Cooper Institute Center for Human Performance and Nutrition Research is 
investigating a new nutrition supplement to lower blood cholesterol. 
The supplement is serum-derived, allergy-free, lactose-free protein.  
 
Pilot study data suggests that this product may be as effective as contemporary 
cholesterol lowering medications and appears to target LDL cholesterol. 
 
ELIGIBLE PARTICIPANTS WILL NEED TO: 
1. Be between 25 and 70 years of age,  
2. Have a total cholesterol between 210 and 270 mg/dL,  
3. Not be taking any cholesterol-lowering medications,  
4. Not be taking new vitamins for less than 3 months. If you have been taking 
vitamins for more than 3 months and are willing to continue their usage, this is 
okay,  
5. Not be pregnant or breast-feeding, 
6. Not be a diabetic individual. 
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** The length of the study is 8-weeks. 
Eligible participants for the study will be expected to make an eight-week 
commitment to the project, which will include five visits to the Cooper Institute to 
have blood drawn. All participants will be financially reimbursed for their time.  
 
If you are interested in participating or would like to learn more, please contact 
Dr. Conrad Earnest at: 972-341-3239. 
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SUBJECT RECRUITMENT FLYER  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________ 
*Reprinted with permission from Dr. Conrad P. Earnest, Director of the Center for Human 
 Performance & Nutrition Research at The Cooper Institute Centers for Integrated Health 
 Research, Dallas, TX.  
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PARTICIPANT INFORMED CONSENT DOCUMENT 
 
 
 
 
 
 
 
 
 
 
 
  ∗Reprinted with permission from Dr. Conrad P. Earnest, Director of the Center for Human 
 Performance & Nutrition Research at The Cooper Institute Centers for Integrated Health 
 Research, Dallas, TX. 
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Informed Consent Document: 
Consent Form 
 
The Cooper Institute 
12330 Preston Road 
Dallas, TX  75230 
 
Principal Investigator:  Dr. Conrad Earnest 
 
You have volunteered as a candidate for this study because you have a total cholesterol 
concentration ranging between 210 and 280 mg/dL, are between the ages of 25 and 70 years 
old, and have no known major health problems. The following information describes the study 
and your role as a participant.  The investigators will answer any questions you may have about 
the study, this consent form, and your participation in the project.  Please read this form 
carefully, and do not hesitate to ask questions about any aspect of the study. 
 
Purpose 
The purpose of the study is to evaluate the effectiveness of a serum-derived nutritional 
supplement, consumed in capsular form, on selected blood cholesterol concentrations, namely 
total and LDL blood cholesterol concentrations. 
 
Procedures 
Individuals who agree to participate and who meet all eligibility criteria will be randomly assigned 
to one of two groups.  Random assignment means your group assignment is determined by 
chance, and you will not be able to choose one group over the others. However, if you are 
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assigned to the placebo group, you will receive 8 weeks worth of the active product following 
your successful completion of the trial to try on your own. 
 
All groups will participate in an 8-week trial. 
Individuals will be assigned to 1 of 2 groups. 
 
1) Receive a serum-derived treatment in capsule form for an 8 week period. 
2) Receive a placebo capsule for a 8 week period. 
 
ALL STUDY PARTICIPANTS WILL BE ASKED TO COMPLETE QUESTIONNAIRES 
CONCERNING YOUR MEDICAL HISTORY, YOUR FOOD INTAKE, AT BASELINE AND 8 
WEEKS.  BLOOD DRAWS WILL TAKE PLACE FIVE (5) TIMES THROUGHOUT THE STUDY 
PERIOD. 
 
Discomforts and Risks 
The risks of participating in the Proliant Health Industries Cholesterol study are small.  You may 
experience temporary pain during the blood drawing, with later bruising at the puncture site.  
Only specially trained staff will be responsible for collection of blood samples.  Also, any samples 
collected during the course of the trial will be tested for biological hazards if they are involved in 
an incident that results in exposure of any individual to potentially hazardous biologic material.   
Emergency equipment and trained personnel are available to deal with unusual situations that 
may arise. 
 
Exclusions 
IF YOU DONATE BLOOD DURING THE TRIAL, IF YOU SMOKE, CONSUME ALCOHOLIC 
BEVERAGES EXCEEDING AN AVERAGE OF 3 DRINKS PER DAY, OR CONSUME COFFEE 
IN EXCESS OF 3 CUPS PER DAY, YOU WILL BE EXCLUDED FROM THE STUDY.  IN 
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ADDITION, IF YOU HAVE PLANS TO BECOME PREGNANT; OR ARE BREASTFEEDING, 
YOU WILL BE EXCLUDED FROM THE STUDY. 
 
Voluntary Participation 
Participation in the Proliant Health Industries Cholesterol study is voluntary. Refusal to 
participate will involve no loss of benefits to which you are entitled.  Further, you may withdraw 
from the study at any time without penalty.  If you decide to withdraw from the study, we request 
that you notify the Project Director, Dr. Conrad Earnest, of your decision in writing. At that time, 
we also request that you complete an exit interview by mail or telephone to enable us to 
determine the reason for withdrawing from the study. 
 
Significant Findings 
You will be told of any significant findings that may occur during the course of this study that 
could relate to your willingness to continue to participate. The investigator and the sponsor 
reserve the right to terminate the study and discontinue your participation at any time for any 
reason, in order to ensure your safety. 
 
Benefits to Participants 
There is no cost for participation in this study. At the conclusion of the trial, you will receive an 
individualized report on your free lipids and other lab test results. 
 
Project Funding 
This project is funded by private donations. 
 
Compensation for Medical Treatment 
If you suffer any adverse experience during the testing, study staff will render first aid and 
emergency care.  The project physician will not provide medical care outside test supervision. 
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Confidentiality 
Only you and the investigators will have access to your study records and other data obtained 
from the study as required by the Privacy Act, 5, U.S.C. 522a.   Details from your medical 
records will be stored on a private computer, but your name will not be used as an identifier.  
Information stored on the computer may be seen by Proliant Health Industries Cholesterol study 
staff.  Your name will not appear in any publications; only group data will be used.  If for any 
reason you desire for us to share any and/or all your data with someone else, a signed letter 
stating your desire to release this information and to whom it should be released will be required. 
 
Questions 
Your signature indicates the investigators or other members of study staff have answered all 
your questions about the study and your participation in the study.  If you should have additional 
questions during the course of the study, or if any problems arise, you should contact the 
Principal Investigator and Project Director, Dr. Conrad Earnest at 972-341-3284. If you have 
questions about your rights as a research study participant, contact Dr Steve Farrell the 
Institutional Review Board Chairman, at The Cooper Institute at 9720-341-3275. 
  
Authorization 
You are making a decision whether or not to participate in this study.  You should not sign until 
you understand all the information presented in the previous pages and until all your questions 
about the research have been answered to your satisfaction.  Your signature indicates that you 
have decided to participate after having read (or been read) the information provided above. 
 
I understand that I am not waiving any legal rights or releasing the local institution sponsoring 
this study or its agents from liability for negligence.  I understand that in the event of physical 
injury resulting from the research procedures, the local institution sponsoring this study does not 
have funds budgeted for compensation either for lost wages or for medical treatment.  Therefore, 
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aside from the emergency care previously described, the local institution does not provide for 
treatment or reimbursements for such injuries. 
 
 
Name (Please print.)_____________________________________________ 
 
Signature _____________________________________________________ 
 
Date ______________________________ 
 
Witness ______________________________Date ___________________ 
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APPENDIX D 
PROLIANT IMMUNOLIN™ PRODUCT CERTIFICATE OF ORIGIN AND 
PRODUCT PURITY FROM BSE CONTAMINATION  
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Table A-1 
Linear regression analysis of change in TC within treatment group regressed on change 
in dietary protein intake 
Independent variable Regression coefficient  
       
Change in dietary protein - 0.19 (0.05)1,2 
 
Constant - 11.75 (2.18) 
 
Adjusted R2  0.13 
 
n  83 
1 SE in parentheses. 
2 Significantly different from zero, P <.0005 
 
 
 
Table A-2   
Linear regression analysis of change in TC within treatment group regressed on change 
in dietary carbohydrate intake 
Independent variable Regression coefficient  
       
Change in dietary carbohydrates - 0.07 (0.02)1,2 
 
Constant - 11.46 (2.22) 
 
Adjusted R2  0.11 
 
n  83 
1 SE in parentheses. 
2 Significantly different from zero, P <.0014 
 
 
 
Table A-3   
Linear regression analysis of change in TC within treatment group regressed on change 
in dietary fat intake 
Independent variable Regression coefficient  
       
Change in dietary fat - 0.17 (0.05)1,2 
 
Constant - 12.50 (2.19) 
 
Adjusted R2  0.11 
 
n  83 
1 SE in parentheses. 
2 Significantly different from zero, P <.0011 
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Table A-4 
Linear regression analysis of change in TC within treatment group regressed on change 
in dietary cholesterol intake 
Independent variable Regression coefficient  
       
Change in dietary cholesterol - 0.04 (0.01)1,2 
 
Constant - 11.23 (2.22) 
 
Adjusted R2  0.11 
 
n  83 
1 SE in parentheses. 
2 Significantly different from zero, P <.0010 
 
 
 
Table A-5   
Linear regression analysis of change in TC within placebo group regressed on change in 
dietary protein intake 
Independent variable Regression coefficient  
       
Change in dietary protein - 0.01 (0.04)1,2 
 
Constant - 1.42 (2.05) 
 
Adjusted R2 - 0.01 
 
N  86 
1 SE in parentheses. 
2 Significantly different from zero, P <0.8202 
 
 
 
Table A-6 
Linear regression analysis of change in TC within placebo group regressed on change in 
dietary carbohydrate intake 
Independent variable Regression coefficient  
       
Change in dietary carbohydrates  0.01 (0.01)1,2 
 
Constant - 2.07 (1.97) 
 
Adjusted R2 - 0.01 
 
N  86 
1 SE in parentheses. 
2 Significantly different from zero, P <0.4664 
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Table A-7 
Linear regression analysis of change in TC within placebo group regressed on change in 
dietary fat intake 
Independent variable Regression coefficient  
       
Change in dietary fat  0.02 (0.04)1,2 
 
Constant - 2.00 (2.03) 
 
Adjusted R2 - 0.01 
 
N  86 
1 SE in parentheses. 
2 Significantly different from zero, P <0.6182 
 
 
 
 
Table A-8 
Linear regression analysis of change in TC within placebo group regressed on change in 
dietary cholesterol intake 
Independent variable Regression coefficient  
       
Change in dietary cholesterol - 0.01 (0.01)1,2 
 
Constant - 1.12 (2.01) 
 
Adjusted R2 - 0.01 
 
N  86 
1 SE in parentheses. 
2 Significantly different from zero, P <0.4986 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           
 
125 
 
VITA 
 
Name:  Melinda Lori Black 
 
Address: 3932 Davila Drive, Dallas, TX 75220 
 
Email Address:  mynutritionist@sbcglobal.net 
 
 
Education: B.S., Dietetics and Institutional Administration, Texas Woman’s  
  University, 1993. 
  M.S., Nutrition, Texas A&M University, 2005. 
 
 
 
 
 
